0001140361-25-010772 | 10-K | XBRL Viewer

Print Document

Stock-Based Compensation, Restricted Stock Units (Details) - Restricted Stock Units [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Number of Units [Abstract]
Unvested balance at beginning of period (in shares)	2,265	11,960
Granted (in shares)		17,959
Vested (in shares)	(2,265)	(17,944)
Forfeited and expired (in shares)		(9,710)
Unvested balance at end of period (in shares)	0	2,265
Weighted-Average Grant Date Fair Value [Abstract]
Unvested balance at beginning of period (in dollars per share)	$ 10.3	$ 11.25
Granted (in dollars per share)		10.3
Vested (in dollars per share)	10.3	10.93
Forfeited and expired (in dollars per share)		10.3
Unvested balance at end of period (in dollars per share)	$ 0	$ 10.3
Unrecognized Compensation Expense [Abstract]
Unrecognized compensation expense	$ 0

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2024	Mar. 20, 2025	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Document Transition Report	false
Entity File Number	0-11635
Entity Registrant Name	STRATA SKIN SCIENCES, INC.
Entity Central Index Key	0001051514
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3986004
Entity Address, Address Line One	5 Walnut Grove Drive
Entity Address, Address Line Two	Suite 140
Entity Address, City or Town	Horsham
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19044
City Area Code	215
Local Phone Number	619-3200
Title of 12(b) Security	Common Stock, $0.001 Par Value
Trading Symbol	SSKN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 4,958,532
Entity Common Stock, Shares Outstanding		4,171,161
Auditor Firm ID	688
Auditor Name	Marcum LLP
Auditor Location	Philadelphia, Pennsylvania

Leases

12 Months Ended

Dec. 31, 2024

Leases [Abstract]

Leases

6. Leases

The Company recognizes right-of-use assets (“ROU assets”) and operating lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than 12 months. The Company adopted the short-term accounting election for leases with a duration of less than one year. The Company leases its facilities and certain IT and office equipment under non-cancellable operating leases. All of the Company’s leasing arrangements are classified as operating leases with remaining lease terms ranging from one to five years. In March 2024, the Company terminated the existing lease for its California facility and concurrently executed a new lease that effectively extended the term of the lease for five years, which has been accounted for as a lease modification. The ROU asset and operating lease liability were remeasured at the modification date, resulting in an increase to both balances of $1.0 million during the year ended December 31, 2024. There were no lease modifications during the year ended December 31, 2023.

Operating lease costs were $0.5 million and $0.4 million for the years ended December 31, 2024 and 2023, respectively. Cash paid for amounts included in the measurement of operating lease liabilities was $0.5 million and $0.4 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, the weighted average incremental borrowing rate was 12.18% and 8.60%, respectively, and the weighted average remaining lease term was 4.1 years and 2.0 years, respectively.

The following table summarizes the Company’s operating lease maturities as of December 31, 2024 (in thousands):

Years ending December 31:
2025	$	463
2026		334
2027		290
2028		301
2029		232
Total remaining lease payments		1,620
Less: imputed interest		(373	)
Total lease liabilities	$	1,247

With respect to lease and non-lease components, the Company adopted the practical expedient to account for the lessee arrangement as a single lease component.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation and Summary of Significant Accounting Policies, Impairment of Long-Lived Assets and Intangibles (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Impairment of Long-Lived Assets and Intangibles [Abstract]
Asset impairment charges	$ 0	$ 0

Income Taxes

12 Months Ended

Dec. 31, 2024

Income Taxes [Abstract]

Income Taxes

13. Income Taxes

Income tax expense consists of the following (in thousands):

	Year Ended December 31,
	2024			2023
Current:
Federal	$	—		$	—
State		16			28
		16			28
Deferred:
Federal		(107	)		(68	)
State		(79	)		(52	)
		(186	)		(120	)
Benefit from income taxes	$	(170	)	$	(92	)

Deferred tax assets and liabilities are determined based on the differences between the consolidated financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.

Significant components of the Company’s deferred tax liability for federal income taxes consisted of the following (in thousands):

	December 31,
	2024			2023
Deferred tax assets:
Net operating loss carryforwards	$	46,295		$	46,718
Intangible assets		2,308			2,138
Inventories		57			71
Reserves and accrued expenses		2,068			1,381
Stock-based compensation		162			180
Operating lease liabilities		305			145
Interest expense limitation carryover		1,024			552
Goodwill		239			—
Gross deferred tax assets		52,458			51,185
Less: valuation allowance		(51,671	)		(50,139	)
		787			1,046
Deferred tax liabilities:
Property and equipment		(478	)		(412	)
Operating lease right-of-use assets		(309	)		(154	)
Goodwill		—			(666	)
		(787	)		(1,232	)
Net deferred tax liability	$	—		$	(186	)

In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company’s deferred tax assets as of December 31, 2024. The valuation allowance increased by $1.5 million during the year ended December 31, 2024. The Company does not have unrecognized tax benefits as of December 31, 2024 or 2023. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

The Company had net operating loss (“NOL”) carryforwards for federal and state income tax purposes as follows (in thousands):

	December 31,
	2024		2023
Federal	$	203,490	$	205,212
State	$	62,819	$	63,566

The NOL carryforwards generated prior to 2018 began to expire for federal income tax purposes and begin expiring in 2030 for state income tax purposes. Federal and many state NOLs generated in 2018 and into the future now have an indefinite life.

The NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. To date, the Company has not performed an analysis to determine whether or not ownership changes have occurred since inception.

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:

	Year Ended December 31,
	2024			2023
Federal tax expense at statutory rate		21.00	%		21.00	%
State tax, net of federal benefit		(0.12	)%		0.18	%
Permanent differences		(1.15	)%		(1.89	)%
Other difference and true ups		(3.13	)%		(8.07	)%
Change in valuation allowance		(14.94	)%		(10.38	)%
Effective income tax rate		1.66	%		0.84	%

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022 (“IRA”). The IRA contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock repurchases. The provisions of the IRA did not have an impact on the Company’s consolidated financial statements for the year ended December 31, 2024, as the Company currently does not qualify as a large corporation for the 15% alternative minimum tax and there were no stock repurchases during 2023. The Company will monitor its operations for changes that could impact the applicability of the IRA provisions in future tax years.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Basis of Presentation and Summary of Significant Accounting Policies, Intangible Assets (Details)	Dec. 31, 2024
Minimum [Member]
Intangible Assets [Abstract]
Estimated useful life	3 years
Maximum [Member]
Intangible Assets [Abstract]
Estimated useful life	12 years

Organization and Nature of Business (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2021	Dec. 31, 2024
At-the-Market Equity Offering [Member] \| Maximum [Member]
Liquidity and Going Concern [Abstract]
Amount of additional common stock Company may sell under equity distribution agreement	$ 8.9	$ 8.9

Basis of Presentation and Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Credit card transaction settlement term	5 days	5 days

Intangible Assets and Goodwill (Tables)

12 Months Ended

Dec. 31, 2024

Intangible Assets and Goodwill [Abstract]

Components of Intangible Assets

Intangible assets consist of the following (in thousands):

December 31, 2024	Gross Carrying Value		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(5,415	)	$	285
Product technology		4,808		(3,984	)		824
Customer relationships		6,900		(6,555	)		345
Tradenames		1,500		(1,425	)		75
Pharos customer lists		5,314		(1,495	)		3,819
	$	24,222	$	(18,874	)	$	5,348

December 31, 2023	Gross Carrying Value		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(4,845	)	$	855
Product technology		4,808		(3,866	)		942
Customer relationships		6,900		(5,865	)		1,035
Tradenames		1,500		(1,275	)		225
Pharos customer lists		5,314		(1,052	)		4,262
	$	24,222	$	(16,903	)	$	7,319

Estimated Future Amortization Expense for Intangible Assets

The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years (in thousands):

Years ending December 31:
2025	$	1,266
2026	$	561
2027	$	561
2028	$	561
2029	$	561

Components of Goodwill

Goodwill consists of the following (in thousands):

	December 31,
	2024		2023
Dermatology recurring procedures segment	$	1,813	$	5,674
Dermatology procedures equipment segment		845		845
	$	2,658	$	6,519

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

Basis of Presentation and Summary of Significant Accounting Policies, Concentrations of Credit Risk and Major Customers (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) Customer	Dec. 31, 2023 USD ($) Customer
Concentration of Credit Risk [Abstract]
Revenues	$ 33,562	$ 33,358
Accounts receivable	$ 5,253	$ 4,440
Other Customer [Member]
Concentration of Credit Risk [Abstract]
Number of major customers \| Customer	2	1
Customer Concentration Risk [Member] \| Revenue [Member]
Concentration of Credit Risk [Abstract]
Number of major customers \| Customer	1	1
Customer Concentration Risk [Member] \| Revenue [Member] \| One Customer [Member]
Concentration of Credit Risk [Abstract]
Revenues	$ 4,100	$ 3,300
Concentration risk percentage	12.10%	10.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| One Customer [Member]
Concentration of Credit Risk [Abstract]
Accounts receivable	$ 0	$ 0
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| One Other Customer [Member]
Concentration of Credit Risk [Abstract]
Accounts receivable		$ 700
Concentration risk percentage		16.50%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Two Other Customers [Member]
Concentration of Credit Risk [Abstract]
Accounts receivable	$ 2,200
Concentration risk percentage	42.20%

Basis of Presentation and Summary of Significant Accounting Policies, Advertising Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Advertising Costs [Abstract]
Advertising expense	$ 1.0	$ 0.5

Leases (Details) - USD ($) $ in Thousands	12 Months Ended
Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Lessee, Operating Lease, Description [Abstract]
Extended lease term	5 years
Increase in ROU asset and operating lease liability resulting from lease modification	$ 1,000	$ 0
Operating lease costs	500	400
Cash paid for amounts included in measurement of operating lease liabilities	$ 500	$ 400
Weighted average incremental borrowing rate	12.18%	8.60%
Weighted average remaining lease term	4 years 1 month 6 days	2 years
Operating Lease Maturities [Abstract]
2025	$ 463
2026	334
2027	290
2028	301
2029	232
Total remaining lease payments	1,620
Less: imputed interest	(373)
Total lease liabilities	$ 1,247
Minimum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term	1 year
Maximum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term	5 years

Long-term Debt (Tables)

12 Months Ended

Dec. 31, 2024

Long-term Debt [Abstract]

Future Payments for Long-term Debt

Future minimum principal payments at December 31, 2024 are as follows (in thousands):

Years ending December 31:
2026	$	3,750
2027		7,500
2028		3,750
		15,000
Exit fee		600
		15,600
Less: unamortized debt discount		(408	)
Long-term debt, net	$	15,192

Inventories (Tables)

12 Months Ended

Dec. 31, 2024

Inventories [Abstract]

Inventories

Inventories consist of the following (in thousands):

	December 31,
	2024		2023
Raw materials and work-in-process	$	2,041	$	2,192
Finished goods		205		481
	$	2,246	$	2,673

Stockholders' Equity, Outstanding Common Stock Warrants (Details) - Senior Term Facility [Member] - $ / shares	1 Months Ended
	Jun. 30, 2023	Sep. 30, 2021
Warrants and Rights [Abstract]
Warrants issued (in shares)	80,000	37,362
Exercise price (in dollars per share)	$ 8.8	$ 18.2

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Allowance for credit losses	$ 433	$ 222
Stockholders' equity:
Series C Convertible Preferred Stock, par value (in dollars per share)	$ 0.1	$ 0.1
Series C Convertible Preferred Stock, shares authorized (in shares)	10,000,000	10,000,000
Series C Convertible Preferred Stock, shares issued (in shares)	0	0
Series C Convertible Preferred Stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	4,171,161	3,506,025
Common stock, shares outstanding (in shares)	4,171,161	3,506,025

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2024

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

8. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	December 31,
	2024		2023
Warranty obligations	$	213	$	180
Compensation and related benefits		1,781		1,679
State sales, use and other taxes		6,371		4,316
Professional fees and other		228		131
	$	8,593	$	6,306

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current [Abstract]
Federal	$ 0	$ 0
State	16	28
Current income tax	16	28
Deferred [Abstract]
Federal	(107)	(68)
State	(79)	(52)
Deferred income tax	(186)	(120)
Benefit from income taxes	(170)	(92)
Deferred Tax Assets [Abstract]
Net operating loss carryforwards	46,295	46,718
Intangible assets	2,308	2,138
Inventories	57	71
Reserves and accrued expenses	2,068	1,381
Stock-based compensation	162	180
Operating lease liabilities	305	145
Interest expense limitation carryover	1,024	552
Goodwill	239	0
Gross deferred tax assets	52,458	51,185
Less: valuation allowance	(51,671)	(50,139)
Net deferred tax assets	787	1,046
Deferred Tax Liabilities [Abstract]
Property and equipment	(478)	(412)
Operating lease right-of-use assets	(309)	(154)
Goodwill	0	(666)
Gross deferred tax liabilities	(787)	(1,232)
Net deferred tax liability	0	(186)
Valuation allowance - Deferred tax asset change in amount	1,500
Unrecognized tax benefits	$ 0	$ 0
Effective Income Tax Rate Reconciliation [Abstract]
Federal tax expense at statutory rate	21.00%	21.00%
State tax, net of federal benefit	(0.12%)	0.18%
Permanent differences	(1.15%)	(1.89%)
Other difference and true ups	(3.13%)	(8.07%)
Change in valuation allowance	(14.94%)	(10.38%)
Effective income tax rate	1.66%	0.84%
Federal [Member]
Operating Loss Carryforwards [Abstract]
Operating loss carryforwards	$ 203,490	$ 205,212
State [Member]
Operating Loss Carryforwards [Abstract]
Operating loss carryforwards	$ 62,819	$ 63,566

Property and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2024

Property and Equipment, net [Abstract]

Components of Property and Equipment

Property and equipment consist of the following (in thousands):

	December 31,
	2024			2023
Lasers placed-in-service	$	33,489		$	32,095
Equipment, computer hardware and software		300			293
Furniture and fixtures		240			240
Leasehold improvements		87			203
Lasers-in-process		2,093			3,231
		36,209			36,062
Less: accumulated depreciation and amortization		(26,148	)		(24,284	)
	$	10,061		$	11,778

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Future Undiscounted Fixed Treatment Code Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 500	$ 700
Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	5,474
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers		$ 300
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 200
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 1,775
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 1,586
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 1,323
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 790
Expected timing of satisfaction period	1 year

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (10,086)	$ (10,830)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	4,968	5,553
Impairment of goodwill	3,861	2,284
Amortization of operating lease right-of-use assets	339	349
Amortization of deferred financing costs and debt discount	148	140
Change in allowance for credit losses	(182)	(110)
Stock-based compensation expense	427	1,303
Loss on debt extinguishment	0	909
Loss on disposal of property and equipment	49	72
Inventory write-off	162	0
Deferred income taxes	(186)	(120)
Changes in operating assets and liabilities:
Accounts receivable	(631)	141
Inventories	572	689
Prepaid expenses and other assets	(189)	246
Accounts payable	(954)	(100)
Accrued expenses and other liabilities	2,266	(197)
Deferred revenues	(57)	(472)
Operating lease liabilities	(319)	(376)
Net cash provided by (used in) operating activities	188	(519)
Cash flows from investing activities:
Purchase of property and equipment	(1,636)	(5,019)
Net cash used in investing activities	(1,636)	(5,019)
Cash flows from financing activities:
Proceeds from long-term debt	0	7,000
Payment of deferred financing costs	0	(97)
Payment of contingent consideration	(18)	(42)
Sale of common stock, net of offering costs	1,943	0
Net cash provided by financing activities	1,925	6,861
Net increase in cash, cash equivalents and restricted cash	477	1,323
Cash, cash equivalents and restricted cash at beginning of year	8,118	6,795
Cash, cash equivalents and restricted cash at end of year	8,595	8,118
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	1,973	1,415
Cash paid during the year for income taxes	23	22
Supplemental schedule of non-cash operating, investing and financing activities:
Modification of common stock warrants	0	384
Transfer of property and equipment to inventories	307	267
Change in intangible assets and fair value of contingent consideration	0	7,374
Accrued exit fee recorded as debt discount	150	450
Accrued payment of contingent consideration	44	18
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	$ 977	$ 0

Long-term Debt

12 Months Ended

Dec. 31, 2024

Long-term Debt [Abstract]

Long-term Debt

9. Long-Term Debt

On September 30, 2021, the Company entered into a credit and security agreement with MidCap Financial Trust (“MidCap”), also acting as the administrative agent, and the lenders identified therein. The original terms provided for an $8.0 million senior term loan. Borrowings under the senior term loan originally bore interest at LIBOR (with a LIBOR floor rate of 0.50%) plus 7.50% per year and were scheduled to mature on September 1, 2026, unless terminated earlier. The Company was obligated to make monthly interest-only payments through September 30, 2024. The credit and security agreement was amended on January 10, 2022 to provide MidCap’s consent to the TheraClear asset acquisition. On September 6, 2022, the Company amended the facility to transition, upon the cessation of LIBOR, to bear interest at one-month Secured Overnight Financing Rate (“SOFR”), or such other applicable period, plus 0.10%, with a floor of 0.50%.

On June 30, 2023, the Company entered into (a) Amendment No. 3 to the credit and security agreement (the “Third Amendment”); (b) the Amended and Restated Warrant Agreement (the “A&R Warrant”) with MidCap Funding XXVII Trust (together with any registered holder from time to time or any holder of the shares issuable or issued upon the exercise or conversion of the warrant, the “Warrantholder”), which amended and restated the warrant agreement to purchase shares of the common stock of the Company, dated as of September 30, 2021 (the “Prior Warrant”), with the Warrantholder; (c) the Amended and Restated Registration Rights Agreement (the “A&R Registration Rights Agreement”) with the Warrantholder, which amended and restated the registration rights agreement, dated as of September 30, 2021, with the Warrantholder; and (d) a letter agreement (the “Fee Letter Agreement”) with MidCap, as agent.

On February 20, 2024, the Company entered into (a) Amendment No. 4 to the credit and security agreement (the “Fourth Amendment”), which amended the credit and security agreement, and (b) a second amended and restated letter agreement (“Amended Fee Letter Agreement”) with MidCap, as agent.

On March 27, 2024, the Company entered into Amendment No. 5 to the credit and security agreement (the “Fifth Amendment”), which further amended the credit and security agreement (as amended to date, the “Senior Term Facility”) to clarify certain provisions related to the maintenance of cash collateral accounts.

The Senior Term Facility provides for a senior secured term loan facility of $20.0 million, of which $8.0 million was drawn by the Company on September 30, 2021 (“Credit Facility #1”), $7.0 million was drawn by the Company on June 30, 2023 (“Credit Facility #2”), and an additional $5.0 million tranche (“Credit Facility #3”) was available to be drawn by the Company if its Dermatology Recurring Procedures Revenue (as defined in the Senior Term Facility) for the preceding 12 calendar months (ending on the last day of the calendar month for which a compliance certificate is delivered) was greater than or equal to $30.0 million (such condition, the “Applicable Funding Condition”). Credit Facility #3 could have been drawn beginning on the later of the satisfaction of the Applicable Funding Condition and January 1, 2024, with such commitment terminating on the earlier to occur of December 31, 2024 and the delivery of a written notice by MidCap to the Company terminating the applicable commitments following an Event of Default (as defined in the Senior Term Facility) that has not been waived or cured at the time such notice is delivered. The Company did not meet the Applicable Funding Condition and, as of December 31, 2024, Credit Facility #3 is no longer available. All borrowings are secured by substantially all of the Company’s assets.

Borrowings under the Senior Term Facility bear interest at a rate per annum equal to the sum of (a) the greater of (i) the sum of (A) 30-day forward-looking term rate of one month SOFR, as published by CME Group Benchmark Administration Limited, from time to time, plus (B) 0.10%, and (ii) the applicable floor rate of 3.50%, with such sum reset monthly, and (b) 7.50%. The effective interest rate of the Senior Term Facility as of December 31, 2024 and 2023 was 13.16% and 13.68%, respectively. The Company is obligated to make interest-only payments (payable monthly in arrears) through June 1, 2026. Commencing on July 1, 2026 and continuing for the remaining 24 months of the facility, the Company will be required to make monthly interest payments and monthly principal payments based on a straight-line amortization schedule set forth in the Senior Term Facility, subject to certain adjustments as described in the Senior Term Facility. The final maturity date under the Senior Term Facility is June 1, 2028, unless earlier terminated. The Senior Term Facility requires the Company to dedicate 100% of certain insurance proceeds to the prepayment of the outstanding term loan, subject to certain exceptions and net of certain expenses and repayments.

The Company may voluntarily prepay the outstanding term loan under the Senior Term Facility, with such prepayment in an amount of at least $5.0 million, at any time upon 30 days’ written notice. Upon prepayment, the Company will be required to pay a prepayment fee equal to (i) 4.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made within 12 months of February 20, 2024, (ii) 3.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 12 months and 24 months after February 20, 2024, (iii) 2.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 24 months and 36 months after February 20, 2024, or (iv) 1.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made after 36 months after February 20, 2024 and prior to the maturity date.

The Senior Term Facility contains certain customary representations and warranties, affirmative covenants and conditions, as well as various negative covenants. Further, the Senior Term Facility contains (a) a quarterly financial covenant that requires the Company to not have less than $30.5 million of net revenue (raised to $33.0 million by December 31, 2026 and, for periods ending after December 31, 2026, such net revenue as determined in good faith by MidCap, which shall not be less than the applicable minimum net revenue amount for the immediately preceding period and $33.0 million) for the trailing 12-month period as of March 31, 2025, and (b) a minimum of unrestricted cash (as defined in the Senior Term Facility), at all times, of not less than $3.0 million. At December 31, 2024, the Company was in compliance with all financial covenants within the Senior Term Facility.

Upon the occurrence and during the continuance of an event of default, MidCap may, and at the direction of a requisite percentage of the lenders must, (i) suspend or terminate the term loan commitment and MidCap and the other lenders’ obligations with respect thereto, and (ii) by notice to the Company, declare all or any portion of the obligations under the Senior Term Facility to be immediately due and payable. In addition to MidCap’s other rights and available remedies, but subject to applicable cure periods, upon the occurrence and during the continuance of an event of default, MidCap may, and at the direction of a requisite percentage of the lenders must, terminate the Senior Term Facility. At December 31, 2024, no event of default had occurred, and the Company believed that events or conditions having a material adverse effect, giving rise to an acceleration of any amounts outstanding under the Senior Term Facility, had not occurred and were remote.

Pursuant to the Amended Fee Letter Agreement, the Company agreed to pay MidCap, as administrative agent, the following fees: (a) an origination fee on June 30, 2023 in an amount equal to (i) the Credit Extensions (as defined in the Senior Term Facility) in respect of Credit Facility #2, multiplied by (ii) 0.50%; (b) on the maturity date of the Senior Term Facility or any earlier date on which the obligations thereunder become due and payable in full or are otherwise paid in full (such date, the “Full Exit Fee Payment Date”), the Company shall pay an exit fee equal to (i) 4.00% of the total aggregate principal amount of Credit Extensions (as defined in the Senior Term Facility) made pursuant to the Senior Term Facility (regardless of any repayment or prepayment thereof) as of the Full Exit Fee Payment Date (such aggregate amount, the “Exit Fee Base Amount”), less (ii) any Partial Exit Fee (as defined below) previously paid; (c) on the date of any voluntary or mandatory partial prepayment of the borrowings under the Senior Term Facility (or on the date such mandatory prepayment becomes due and payable) (each such date, a “Partial Exit Fee Payment Date”), the Company shall pay an exit fee equal to 4.00% of the principal amount of the credit facilities paid or prepaid (or required to be paid in the case of a mandatory prepayment) as of the Partial Exit Fee Payment Date (such amount, the “Partial Exit Fee”); and (d) an origination fee payable contemporaneously with funding Credit Facility #3 in an amount equal to (i) the Credit Extensions (as defined in the Senior Term Facility) in respect of Credit Facility #3, multiplied by (ii) 0.50%.

The Prior Warrant allowed the Warrantholder, an affiliate of the lender, to purchase 37,362 shares of the Company’s common stock at an exercise price equal to $18.20 per share for a 10-year period ending September 30, 2031. Pursuant to, and in accordance with, the terms and conditions of the A&R Warrant, which amended and restated the Prior Warrant, the Warrantholder can purchase 80,000 shares of the Company’s common stock at an exercise price equal to $8.80 per share for a 10-year period ending on June 30, 2033. Pursuant to the A&R Registration Rights Agreement, the Company registered the shares underlying the A&R Warrant effective August 18, 2023. The amendment of the warrant resulted in an increase in the fair value of the warrant, which has been accounted for as a lender fee.

The Third Amendment was accounted for as a debt extinguishment, as the new loan was considered substantially different from the original loan. The Company recorded a loss on debt extinguishment of $0.9 million for the year ended December 31, 2023, which included unamortized debt discount on the original loan of $0.4 million, an increase in the fair value of the warrant of $0.4 million and lender fees of $0.1 million. The Fourth Amendment has been accounted for as a debt modification, as the new loan is not considered substantially different from the existing loan. In connection with the Fourth Amendment, the Company increased the accrued exit fee, which is recorded as both a debt discount and an increase to the principal amount of debt, to $0.6 million. The debt discount, which also includes third party costs incurred in connection with the Third Amendment of $13.0 thousand, is being recognized as interest expense over the term of the Senior Term Facility using the effective-interest method. The unamortized debt discount was $0.4 million as of both December 31, 2024 and 2023. The Company recognized interest expense of $2.1 million during the year ended December 31, 2024, of which $0.1 million was related to the amortization of the debt discount. The Company recognized interest expense of $1.6 million during the year ended December 31, 2023, of which $0.1 million was related to the amortization of the debt discount.

Future minimum principal payments at December 31, 2024 are as follows (in thousands):

Years ending December 31:
2026	$	3,750
2027		7,500
2028		3,750
		15,000
Exit fee		600
		15,600
Less: unamortized debt discount		(408	)
Long-term debt, net	$	15,192

Basis of Presentation and Summary of Significant Accounting Policies, Restricted Cash (Details) - USD ($) $ in Thousands	Oct. 22, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restricted Cash [Abstract]
Appellate bond of company	$ 1,300
Cash and cash equivalents		$ 7,261	$ 6,784
Restricted cash		1,334	1,334
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows		$ 8,595	$ 8,118	$ 6,795

Business and Geographical Reporting Segments, Depreciation and Amortization by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Depreciation and Amortization by Reportable Segment [Abstract]
Depreciation and amortization	$ 4,968	$ 5,553
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Depreciation and Amortization by Reportable Segment [Abstract]
Depreciation and amortization	4,471	4,793
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Depreciation and Amortization by Reportable Segment [Abstract]
Depreciation and amortization	485	746
Unallocated [Member]
Depreciation and Amortization by Reportable Segment [Abstract]
Depreciation and amortization	$ 12	$ 14

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2024

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	December 31,
	2024		2023
Warranty obligations	$	213	$	180
Compensation and related benefits		1,781		1,679
State sales, use and other taxes		6,371		4,316
Professional fees and other		228		131
	$	8,593	$	6,306

Intangible Assets and Goodwill, Components of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Components of Goodwill [Abstract]
Goodwill	$ 2,658	$ 6,519
Impairment of goodwill	3,861	2,284
Dermatology Recurring Procedures [Member]
Components of Goodwill [Abstract]
Goodwill	1,813	5,674
Impairment of goodwill	3,900	2,300
Dermatology Procedures Equipment [Member]
Components of Goodwill [Abstract]
Goodwill	$ 845	$ 845

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Business and Geographical Reporting Segments, Results of Operations from Business Segments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) Segment	Dec. 31, 2023 USD ($)
Business Segments [Abstract]
Number of operating segments \| Segment	2
Results of Operations from Business Segments [Abstract]
Revenues	$ 33,562	$ 33,358
Cost of revenues	14,481	14,897
Gross profit	$ 19,081	$ 18,461
Gross profit %	56.90%	55.30%
Allocated expenses [Abstract]
Engineering and product development	$ 883	$ 1,317
Selling and marketing	12,289	12,956
Impairment of goodwill	3,861	2,284
Unallocated expenses	11,303	10,508
Total operating expenses	28,336	27,065
(Loss) income from operations	(9,255)	(8,604)
Interest expense	(2,107)	(1,640)
Interest income	242	231
Other income	864	0
Loss on debt extinguishment	0	(909)
(Loss) income before benefit from income taxes	(10,256)	(10,922)
Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	21,171	21,530
Allocated expenses [Abstract]
Impairment of goodwill	3,900	2,300
Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	12,391	11,828
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	21,171	21,530
Cost of revenues	7,893	8,729
Gross profit	$ 13,278	$ 12,801
Gross profit %	62.70%	59.50%
Allocated expenses [Abstract]
Engineering and product development	$ 658	$ 1,011
Selling and marketing	11,046	11,169
Impairment of goodwill	3,861	2,284
Unallocated expenses	0	0
Total operating expenses	15,565	14,464
(Loss) income from operations	(2,287)	(1,663)
Interest expense	0	0
Interest income	0	0
Other income	0
Loss on debt extinguishment		0
(Loss) income before benefit from income taxes	(2,287)	(1,663)
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	12,391	11,828
Cost of revenues	6,588	6,168
Gross profit	$ 5,803	$ 5,660
Gross profit %	46.80%	47.90%
Allocated expenses [Abstract]
Engineering and product development	$ 225	$ 306
Selling and marketing	1,243	1,787
Impairment of goodwill	0	0
Unallocated expenses	0	0
Total operating expenses	1,468	2,093
(Loss) income from operations	4,335	3,567
Interest expense	0	0
Interest income	0	0
Other income	0
Loss on debt extinguishment		0
(Loss) income before benefit from income taxes	$ 4,335	$ 3,567

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Contract Liabilities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Contract with Customer, Liability [Abstract]
Short-term contract liabilities	$ 0.2	$ 0.3
Long-term contract liabilities	0.3	0.4
Change in Contract with Customer, Liability [Abstract]
Contract liabilities recognized as revenue	$ 0.3	$ 0.4

Basis of Presentation and Summary of Significant Accounting Policies, Contingent Consideration (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Contingent Consideration [Abstract]
Reduction in contingent consideration adjusted to carrying value of technology intangible asset	$ 0.0
TheraClear Corporation [Member]
Contingent Consideration [Abstract]
Risk free rate of return		3.80%
Revenue volatility		15.00%
Cost of equity		10.00%
Fair value of contingent consideration		$ 1.2
Reduction in contingent consideration adjusted to carrying value of technology intangible asset		$ (7.4)

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Abstract]
Revenues, net	$ 33,562	$ 33,358
Dermatology Recurring Procedures [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	21,171	21,530
Dermatology Procedures Equipment [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	$ 12,391	$ 11,828

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2024

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Restricted Cash

The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2024		2023
Cash and cash equivalents	$	7,261	$	6,784
Restricted cash		1,334		1,334
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	8,595	$	8,118

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2024 and 2023 is summarized as follows (in thousands):

	December 31,
	2024			2023
Balance, beginning of year	$	303		$	207
Additions		156			237
Expirations and claims satisfied		(144	)		(141	)
Total		315			303
Less current portion within accrued expenses and other current liabilities		(213	)		(180	)
Balance within deferred revenues and other liabilities	$	102		$	123

Disaggregation of Revenue

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2024		2023
Dermatology recurring procedures	$	21,171	$	21,530
Dermatology procedures equipment		12,391		11,828
Total net revenues	$	33,562	$	33,358

Future Undiscounted Fixed Treatment Code Payments

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international dermatology recurring procedures, the Company’s only long-term arrangements (in thousands):

Years ending December 31:
2025	$	1,775
2026		1,586
2027		1,323
2028		790
	$	5,474

Antidilutive Securities Excluded from Computation of Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2024		2023
Stock options		521,726		772,864
Common stock warrants		80,000		80,000
Restricted stock units		2,265		2,265
		603,991		855,129

Stock-Based Compensation, Summary (Details) - USD ($) $ in Millions		1 Months Ended	3 Months Ended	12 Months Ended
	Apr. 03, 2023	Oct. 31, 2023	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Stock-based Compensation [Abstract]
Unvested options to purchase shares of common stock accelerated (in shares)		27,209
Accelerated compensation expense		$ 0.3
Stock Options [Member]
Stock-based Compensation [Abstract]
Granted (in shares)				70,000	454,504
Stock Options [Member] \| Chief Executive Officer [Member]
Stock-based Compensation [Abstract]
Granted (in shares)	15,000
Stock-based options forfeited (in shares)			15,000
2016 Omnibus Incentive Plan [Member]
Stock-based Compensation [Abstract]
Common stock reserved for future issuance (in shares)				7,832,651
Number of shares available for issuance (in shares)				7,270,212

Leases (Tables)

12 Months Ended

Dec. 31, 2024

Leases [Abstract]

Operating Lease Maturities

The following table summarizes the Company’s operating lease maturities as of December 31, 2024 (in thousands):

Years ending December 31:
2025	$	463
2026		334
2027		290
2028		301
2029		232
Total remaining lease payments		1,620
Less: imputed interest		(373	)
Total lease liabilities	$	1,247

Inventories (Details) - USD ($) $ in Thousands	12 Months Ended
Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Schedule of inventory [Abstract]
Raw materials and work-in-process	$ 2,041	$ 2,192
Finished goods	205	481
Inventories, net	2,246	2,673
Inventories wrote off	$ 162	$ 0

Long-term Debt, Senior Term Facility (Details)		1 Months Ended		3 Months Ended	12 Months Ended
Long-term Debt, Senior Term Facility (Details)	Sep. 06, 2022	Jun. 30, 2023 $ / shares shares	Sep. 30, 2021 $ / shares shares	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($) Payment $ / shares shares	Dec. 31, 2023 USD ($)
Long-term Debt [Abstract]
Loss on debt extinguishment					$ 0	$ (909,000)
Unamortized debt discount					408,000
Exit fee					600,000
SOFR [Member]
Long-term Debt [Abstract]
Term of variable rate	1 month
Basis spread on variable rate	0.10%
Interest rate floor	0.50%
Senior Term Facility [Member]
Long-term Debt [Abstract]
Warrants issued (in shares) \| shares		80,000	37,362
Warrants, exercise price (in dollars per share) \| $ / shares		$ 8.8	$ 18.2
MidCap Financial Trust [Member] \| Senior Term Facility [Member]
Long-term Debt [Abstract]
Face amount of debt					$ 8,000,000
Maturity date					Sep. 01, 2026
Frequency of payment					monthly
Number of monthly principal payments plus interest \| Payment					24
Notice period					30 days
Prepayment fee if prepayment is made within twelve months					4.00%
Prepayment fee if prepayment is made between twelve months and twenty-four months					3.00%
Prepayment fee if prepayment is made between twenty-four months and thirty-six months					2.00%
Prepayment fee if prepayment is made after thirty-six months					1.00%
Minimum net revenue threshold					$ 30,500,000
Minimum net revenue threshold by December 31, 2026					33,000,000
Minimum unrestricted cash					3,000,000
Loss on debt extinguishment						900,000
Unamortized debt discount						400,000
Increase in fair value of warrants						400,000
Lender fees						100,000
Interest expense					2,100,000	1,600,000
Amortization of debt discount					100,000	$ 100,000
MidCap Financial Trust [Member] \| Senior Term Facility [Member] \| Minimum [Member]
Long-term Debt [Abstract]
Prepayment of debt					$ 5,000,000
MidCap Financial Trust [Member] \| Senior Term Facility [Member] \| Forecast [Member]
Long-term Debt [Abstract]
Minimum net revenue threshold by trailing 12-month period				$ 33,000,000
MidCap Financial Trust [Member] \| Senior Term Facility [Member] \| A&R Warrant [Member]
Long-term Debt [Abstract]
Warrants issued (in shares) \| shares					80,000
Warrants, exercise price (in dollars per share) \| $ / shares					$ 8.8
Warrants, expected term					10 years
MidCap Financial Trust [Member] \| Senior Term Facility [Member] \| Common Stock [Member]
Long-term Debt [Abstract]
Warrants issued (in shares) \| shares					37,362
Warrants, exercise price (in dollars per share) \| $ / shares					$ 18.2
Warrants, expected term					10 years
MidCap Financial Trust [Member] \| Senior Term Facility [Member] \| LIBOR [Member]
Long-term Debt [Abstract]
Basis spread on variable rate					7.50%
Interest rate floor					0.50%
MidCap Financial Trust [Member] \| Senior Term Facility, Amendment [Member]
Long-term Debt [Abstract]
Face amount of debt					$ 20,000,000
Forward looking term					30 days
Interest rate floor					3.50%
Amount available to be drawn under condition					$ 30,000,000
Effective interest rate					13.16%	13.68%
Required percentage of certain insurance proceeds					100.00%
MidCap Financial Trust [Member] \| Senior Term Facility, Amendment [Member] \| SOFR [Member]
Long-term Debt [Abstract]
Term of variable rate					1 month
Base interest rate					0.10%
Basis spread on variable rate					7.50%
MidCap Financial Trust [Member] \| Credit Facility #1 [Member]
Long-term Debt [Abstract]
Amount drawn					$ 8,000,000
MidCap Financial Trust [Member] \| Credit Facility #2 [Member]
Long-term Debt [Abstract]
Amount drawn					$ 7,000,000
Percentage of administrative agent fess					0.50%
Percentage of credit extension					4.00%
MidCap Financial Trust [Member] \| Credit Facility #3 [Member]
Long-term Debt [Abstract]
Amount available for amount drawn					$ 5,000,000
Percentage of credit extension					0.50%
Percentage of exit fee					4.00%
MidCap Financial Trust [Member] \| Senior Term Facility, Third Amendment [Member]
Long-term Debt [Abstract]
Unamortized debt discount					$ 400,000	$ 400,000
Third party costs incurred					13,000
MidCap Financial Trust [Member] \| Senior Term Facility, Fourth Amendment [Member]
Long-term Debt [Abstract]
Exit fee					$ 600,000

Basis of Presentation and Summary of Significant Accounting Policies, Accrued Warranty Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Activity of Warranty Accrual [Roll Forward]
Balance, beginning of year	$ 303	$ 207
Additions	156	237
Expirations and claims satisfied	(144)	(141)
Total	315	303
Less current portion within accrued expenses and other current liabilities	(213)	(180)
Balance within deferred revenues and other liabilities	$ 102	$ 123
Minimum [Member]
Accrued Warranty Costs [Abstract]
Standard warranty period	1 year
Offered warranty period	3 years
Maximum [Member]
Accrued Warranty Costs [Abstract]
Standard warranty period	2 years
Offered warranty period	4 years

Basis of Presentation and Summary of Significant Accounting Policies, Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Antidilutive Securities Excluded from Computation of Net Loss Per Share [Abstract]
Potential common stock equivalents (in shares)	603,991	855,129
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Net Loss Per Share [Abstract]
Potential common stock equivalents (in shares)	521,726	772,864
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Net Loss Per Share [Abstract]
Potential common stock equivalents (in shares)	80,000	80,000
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Net Loss Per Share [Abstract]
Potential common stock equivalents (in shares)	2,265	2,265

Stock-Based Compensation, Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Fair Value Assumptions [Abstract]
Expected term (in years)	6 years 5 months 15 days	7 years 5 months 26 days
Expected volatility	77.93%	74.58%
Risk-free interest rate	3.91%	4.38%
Expected dividend rate	0.00%	0.00%

Intangible Assets and Goodwill

12 Months Ended

Dec. 31, 2024

Intangible Assets and Goodwill [Abstract]

Intangible Assets and Goodwill

7. Intangible Assets and Goodwill

Intangible assets consist of the following (in thousands):

December 31, 2024	Gross Carrying Value		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(5,415	)	$	285
Product technology		4,808		(3,984	)		824
Customer relationships		6,900		(6,555	)		345
Tradenames		1,500		(1,425	)		75
Pharos customer lists		5,314		(1,495	)		3,819
	$	24,222	$	(18,874	)	$	5,348

December 31, 2023	Gross Carrying Value		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(4,845	)	$	855
Product technology		4,808		(3,866	)		942
Customer relationships		6,900		(5,865	)		1,035
Tradenames		1,500		(1,275	)		225
Pharos customer lists		5,314		(1,052	)		4,262
	$	24,222	$	(16,903	)	$	7,319

The Company recorded amortization expense of $2.0 million and $2.7 million during the years ended December 31, 2024 and 2023, respectively.

During 2023, the Company revised its projections of expected revenues and gross profits to be earned from TheraClear devices. The fair value of the contingent consideration as of December 31, 2023 was estimated to be $1.2 million, which resulted in a reduction in contingent consideration of $7.4 million with a corresponding adjustment to the carrying value of the product technology intangible asset. There was no such revaluation of the contingent consideration during the year ended December 31, 2024.

The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years (in thousands):

Years ending December 31:
2025	$	1,266
2026	$	561
2027	$	561
2028	$	561
2029	$	561

Goodwill consists of the following (in thousands):

	December 31,
	2024		2023
Dermatology recurring procedures segment	$	1,813	$	5,674
Dermatology procedures equipment segment		845		845
	$	2,658	$	6,519

During the years ended December 31, 2024 and 2023, the Company recognized goodwill impairment charges of $3.9 million and $2.3 million, respectively, related to the dermatology recurring procedures segment primarily driven by a decline in projected cash flows, including revenues and profitability (see Note 2).

Intangible Assets and Goodwill, Components of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Components of Intangible Assets [Abstract]
Gross carrying value	$ 24,222	$ 24,222
Accumulated amortization	(18,874)	(16,903)
Net book value	5,348	7,319
Amortization expense of intangible assets	2,000	2,700
Reduction in contingent consideration adjusted to carrying value of technology intangible asset	0
TheraClear Corporation [Member]
Components of Intangible Assets [Abstract]
Fair value of contingent consideration		1,200
Reduction in contingent consideration adjusted to carrying value of technology intangible asset		(7,400)
Core Technology [Member]
Components of Intangible Assets [Abstract]
Gross carrying value	5,700	5,700
Accumulated amortization	(5,415)	(4,845)
Net book value	285	855
Product Technology [Member]
Components of Intangible Assets [Abstract]
Gross carrying value	4,808	4,808
Accumulated amortization	(3,984)	(3,866)
Net book value	824	942
Customer Relationships [Member]
Components of Intangible Assets [Abstract]
Gross carrying value	6,900	6,900
Accumulated amortization	(6,555)	(5,865)
Net book value	345	1,035
Tradenames [Member]
Components of Intangible Assets [Abstract]
Gross carrying value	1,500	1,500
Accumulated amortization	(1,425)	(1,275)
Net book value	75	225
Pharos Customer Lists [Member]
Components of Intangible Assets [Abstract]
Gross carrying value	5,314	5,314
Accumulated amortization	(1,495)	(1,052)
Net book value	$ 3,819	$ 4,262

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In-Capital [Member]	Accumulated Deficit [Member]	Total
Beginning balance at Dec. 31, 2022	$ 3	$ 249,056	$ (227,228)	$ 21,831
Beginning balance (in shares) at Dec. 31, 2022	3,472,246
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 0	1,303	0	1,303
Issuance of restricted stock	$ 1	(1)	0	$ 0
Issuance of restricted stock (in shares)	33,779			33,779
Modification of common stock warrants	$ 0	384	0	$ 384
Net loss	0	0	(10,830)	(10,830)
Ending balance at Dec. 31, 2023	$ 4	250,742	(238,058)	12,688
Ending balance (in shares) at Dec. 31, 2023	3,506,025
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 0	427	0	$ 427
Issuance of restricted stock (in shares)				0
Sale of common stock, net of offering costs	$ 0	1,943	0	$ 1,943
Sale of common stock, net of offering costs (in shares)	665,136
Net loss	$ 0	0	(10,086)	(10,086)
Ending balance at Dec. 31, 2024	$ 4	$ 253,112	$ (248,144)	$ 4,972
Ending balance (in shares) at Dec. 31, 2024	4,171,161

Basis of Presentation and Summary of Significant Accounting Policies, Employee Retention Credit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Employee Retention Credit [Abstract]
Other income	$ 864	$ 0
Employee Retention Credit [Member]
Employee Retention Credit [Abstract]
Other income	$ 900	$ 0

Basis of Presentation and Summary of Significant Accounting Policies, Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) Unit	Dec. 31, 2023 USD ($)
Goodwill [Abstract]
Number of reporting units \| Unit	2
Goodwill impairment \| $	$ 3,861	$ 2,284
Market Approach [Member]
Goodwill [Abstract]
Percentage of fair value weighting market approach given	25.00%
Income Approach [Member]
Goodwill [Abstract]
Percentage of fair value weighting market approach given	75.00%

Property and Equipment, net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 36,209	$ 36,062
Less: accumulated depreciation and amortization	(26,148)	(24,284)
Property and equipment, net	10,061	11,778
Depreciation and amortization expense	3,000	2,900
Lasers Placed-In-Service [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	33,489	32,095
Equipment, Computer Hardware and Software [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	300	293
Furniture and Fixtures [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	240	240
Leasehold Improvements [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	87	203
Lasers-In-Process [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 2,093	$ 3,231

Commitments and Contingencies, Accrued State Sales and Use Tax Matters and Employee 401(k) Savings Plan (Details) - USD ($) $ in Millions		12 Months Ended
	Oct. 22, 2024	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024
Sales and Use Tax Matters [Abstract]
Appellate bond posted value	$ 1.3
Employee 401(k) Savings Plan [Abstract]
Employer contribution amount		$ 0.3	$ 0.4
Tax Period from March 2014 through November 2022 [Member]
Sales and Use Tax Matters [Abstract]
Appellate bond posted value	$ 1.3
Accrued amount including penalties and interest				$ 1.8
Tax Period from March 2014 through November 2022 [Member] \| Assessment One [Member]
Sales and Use Tax Matters [Abstract]
Estimated tax positions subject to audit		5.2
Assessment amount		1.8
Tax Period from March 2014 through November 2022 [Member] \| Assessment Two [Member]
Sales and Use Tax Matters [Abstract]
Assessment amount				$ 1.3
Tax period from June 2018 through June 2022 [Member]
Sales and Use Tax Matters [Abstract]
Estimated tax positions subject to audit		$ 2.1

Basis of Presentation and Summary of Significant Accounting Policies, Property and Equipment, net (Details)	Dec. 31, 2024
Computers, Hardware and Software [Member]
Property and Equipment, Net [Abstract]
Property and equipment, net, useful life	3 years
Machinery and Equipment [Member]
Property and Equipment, Net [Abstract]
Property and equipment, net, useful life	5 years
Furniture and Fixtures [Member]
Property and Equipment, Net [Abstract]
Property and equipment, net, useful life	7 years

Business and Geographical Reporting Segments, Disaggregation of Revenue by Geographical Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	$ 33,562	$ 33,358
Dermatology Recurring Procedures [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	21,171	21,530
Dermatology Procedures Equipment [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	12,391	11,828
Domestic [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	20,888	23,028
China [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	4,069	3,340
Other Foreign [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	8,605	6,990
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	21,171	21,530
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	12,391	11,828
Operating Segments [Member] \| Domestic [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	19,531	20,215
Operating Segments [Member] \| Domestic [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	1,357	2,813
Operating Segments [Member] \| China [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	0	0
Operating Segments [Member] \| China [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	4,069	3,340
Operating Segments [Member] \| Other Foreign [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	1,640	1,315
Operating Segments [Member] \| Other Foreign [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	$ 6,965	$ 5,675

- Definition

+ References

+ Details

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 7,261	$ 6,784
Restricted cash	1,334	1,334
Accounts receivable, net of allowance for credit losses of $433 and $222 at December 31, 2024 and 2023, respectively	5,253	4,440
Inventories	2,246	2,673
Prepaid expenses and other current assets	501	312
Total current assets	16,595	15,543
Property and equipment, net	10,061	11,778
Operating lease right-of-use assets	1,264	626
Intangible assets, net	5,348	7,319
Goodwill	2,658	6,519
Other assets	231	231
Total assets	36,157	42,016
Current liabilities:
Accounts payable	2,433	3,343
Accrued expenses and other current liabilities	8,593	6,306
Deferred revenues	2,241	2,120
Current portion of operating lease liabilities	328	352
Current portion of contingent consideration	1,030	53
Total current liabilities	14,625	12,174
Long-term debt, net	15,192	15,044
Deferred revenues and other liabilities	353	552
Deferred tax liability	0	186
Operating lease liabilities, net of current portion	919	237
Contingent consideration, net of current portion	96	1,135
Total liabilities	31,185	29,328
Commitments and contingencies (Note 10)
Stockholders' equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 4,171,161 and 3,506,025 shares issued and outstanding at December 31, 2024 and 2023, respectively	4	4
Additional paid-in capital	253,112	250,742
Accumulated deficit	(248,144)	(238,058)
Total stockholders' equity	4,972	12,688
Total liabilities and stockholders' equity	$ 36,157	$ 42,016

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Consolidated Statements of Operations [Abstract]
Revenues, net	$ 33,562	$ 33,358
Cost of revenues	14,481	14,897
Gross profit	19,081	18,461
Operating expenses:
Engineering and product development	883	1,317
Selling and marketing	12,289	12,956
General and administrative	11,303	10,508
Impairment of goodwill	3,861	2,284
Total operating expenses	28,336	27,065
Loss from operations	(9,255)	(8,604)
Other (expense) income:
Interest expense	(2,107)	(1,640)
Interest income	242	231
Loss on debt extinguishment	0	(909)
Other income	864	0
Other (expense), income net	(1,001)	(2,318)
Loss before benefit from income taxes	(10,256)	(10,922)
Benefit from income taxes	170	92
Net loss	$ (10,086)	$ (10,830)
Net loss per share of common stock - basic (in dollars per share)	$ (2.65)	$ (3.1)
Net loss per share of common stock - diluted (in dollars per share)	$ (2.65)	$ (3.1)
Weighted average shares of common stock outstanding - basic (in shares)	3,807,186	3,491,964
Weighted average shares of common stock outstanding - diluted (in shares)	3,807,186	3,491,964

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2024
Lasers Placed-in Service [Member]
Revenue Recognition [Abstract]
Lease term	36 months
Renewal term	1 year
Lasers Placed-in Service [Member] \| Minimum [Member]
Revenue Recognition [Abstract]
Notice period to cancel contract agreement	30 days
Lasers Placed-in Service [Member] \| Maximum [Member]
Revenue Recognition [Abstract]
Notice period to cancel contract agreement	60 days
South Korea [Member]
Revenue Recognition [Abstract]
Lease term	48 months

Basis of Presentation and Summary of Significant Accounting Policies, Reverse Stock Split (Details) - Common Stock [Member]	Apr. 26, 2024 shares
Reverse Stock Split [Abstract]
Reverse stock split ratio	0.1
Fractional shares issued (in shares)	0

Property and Equipment, net

12 Months Ended

Dec. 31, 2024

Property and Equipment, net [Abstract]

Property and Equipment, net

5. Property and Equipment, net

Property and equipment consist of the following (in thousands):

	December 31,
	2024			2023
Lasers placed-in-service	$	33,489		$	32,095
Equipment, computer hardware and software		300			293
Furniture and fixtures		240			240
Leasehold improvements		87			203
Lasers-in-process		2,093			3,231
		36,209			36,062
Less: accumulated depreciation and amortization		(26,148	)		(24,284	)
	$	10,061		$	11,778

The Company recorded depreciation and amortization expense of $3.0 million and $2.9 million during the years ended December 31, 2024 and 2023, respectively.

Inventories

12 Months Ended

Dec. 31, 2024

Inventories [Abstract]

Inventories

4. Inventories

Inventories consist of the following (in thousands):

	December 31,
	2024		2023
Raw materials and work-in-process	$	2,041	$	2,192
Finished goods		205		481
	$	2,246	$	2,673

Due to the expiration in 2024 of extended warranty service contracts that were assumed in August 2021 in connection with the acquisition of Pharos laser system products, the Company wrote off $0.2 million of inventories that will no longer be needed for warranty purposes, which is included in cost of revenues in the consolidated statement of operations.

Commitments and Contingencies, Contingent Consideration and Milestone Payments (Details) $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2022 USD ($) Device	Dec. 31, 2024 USD ($)
Development Agreement [Member]
Contingent Consideration and Milestone Payments [Abstract] [Abstract]
Future milestone payments		$ 0.0
Development Agreement [Member] \| Maximum [Member]
Contingent Consideration and Milestone Payments [Abstract] [Abstract]
Future earnout payments	$ 0.5
Future earnout payment due upon revenue target	0.5
Future milestone payments	$ 3.0
Number of devices in development \| Device	3
Development agreement term		3 years
TheraClear Corporation [Member]
Contingent Consideration and Milestone Payments [Abstract] [Abstract]
Future earnout payment due upon revenue target	$ 1.0
Subsequent period of gross profit for future royalty payments		4 years
Royalty and gross profit payments incurred		$ 0.1
TheraClear Corporation [Member] \| Maximum [Member]
Contingent Consideration and Milestone Payments [Abstract] [Abstract]
Future earnout payments	3.0
Future royalty payments	20.0
Future milestone payments	$ 0.5
TheraClear Corporation [Member] \| Domestic [Member] \| Minimum [Member]
Contingent Consideration and Milestone Payments [Abstract] [Abstract]
Percentage of gross profit for future royalty payments for subsequent period	10.00%
TheraClear Corporation [Member] \| Domestic [Member] \| Maximum [Member]
Contingent Consideration and Milestone Payments [Abstract] [Abstract]
Percentage of gross profit for future royalty payments for subsequent period	20.00%
TheraClear Corporation [Member] \| International [Member]
Contingent Consideration and Milestone Payments [Abstract] [Abstract]
Percentage of gross profit for future royalty payments for subsequent period	25.00%

Stock-Based Compensation

12 Months Ended

Dec. 31, 2024

Stock-Based Compensation [Abstract]

Stock-Based Compensation

12. Stock-Based Compensation

The Company’s 2016 Omnibus Incentive Stock Plan (“2016 Plan”), as amended, has reserved up to 7,832,651 shares of common stock for future issuance. As of December 31, 2024, there were 7,270,212 shares of common stock remaining available for issuance for awards under the 2016 Plan.

The Company measures share‑based awards at their grant‑date fair value and records compensation expense on a straight‑line basis over the requisite service period of the awards. The Company recorded share‑based compensation expense (for all awards and modifications, if any) in the accompanying consolidated statements of operations as follows (in thousands):

	Year Ended December 31,
	2024		2023
Selling and marketing	$	7	$	79
General and administrative		420		1,224
	$	427	$	1,303

On April 3, 2023, the Company granted 15,000 stock-based options to its former Chief Executive Officer. The vesting of these awards was contingent upon meeting one or more financial goals (a performance condition) or a common stock share price (a market condition). The fair value of stock-based awards is determined at the date of grant. Stock-based compensation expense is recorded ratably for market condition awards during the requisite service period and is not reversed, except for forfeitures, at the vesting date regardless of whether the market condition is met. Stock-based compensation expense for performance condition awards is re-evaluated at each reporting period based on the probability of the achievement of the goal. The 15,000 stock-based options were forfeited in the fourth quarter of 2023 due to the Chief Executive Officer’s separation and failure to achieve the vesting conditions.

Also in connection with the separation of the Company’s Chief Executive Officer in October 2023, the vesting of 27,209 unvested options to purchase shares of common stock was accelerated. As this acceleration of vesting occurred in accordance with the terms of the original option agreement, it is not considered a modification for accounting purposes. The Company recognized $0.3 million of share-based compensation expense in connection with the accelerated vesting.

Stock Options

The following table summarizes stock option activity for the years ended December 31, 2024 and 2023:

	Number of Shares Under Option Plan			Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Term (in years)
Outstanding at January 1, 2023		447,462		$	17.20
Granted		454,504		$	6.31
Forfeited and expired		(129,102	)	$	15.59
Outstanding at December 31, 2023		772,864		$	11.07		6.70
Granted		70,000		$	3.22
Forfeited and expired		(321,138	)	$	14.07
Outstanding at December 31, 2024		521,726		$	8.16		7.88
Exercisable at December 31, 2024		208,671		$	12.21		6.32
Vested and expected to vest at December 31, 2024		521,726		$	8.16		7.88

The weighted‑average grant date fair value of options granted was $2.27 and $4.43 per share during the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, the total unrecognized compensation expense related to unvested stock option awards was $1.0 million, which the Company expects to recognize over a weighted‑average period of approximately 2.36 years. The aggregate intrinsic value of options outstanding at December 31, 2024 and 2023 was $8.0 thousand and $0.1 million, respectively. There was no aggregate intrinsic value of options exercisable and no options were exercised during the years ended December 31, 2024 and 2023.

The fair value of options is estimated using the Black-Scholes option pricing model which takes into account inputs such as the exercise price, the value of the underlying common stock at the grant date, expected term, expected volatility, risk free interest rate and dividend yield. The fair value of each grant of options during the year ended December 31, 2024 and 2023 was determined using the methods and assumptions discussed below.

●

The expected term of employee options is based on the observed and expected time to full-vesting, forfeiture and exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. Options expire up to a maximum of ten years from the date of grant.

●

The expected volatility is based on historical volatility of the Company’s common stock.

●

The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.

●

The expected dividend yield is none because the Company has not historically paid and does not expect for the foreseeable future to pay a dividend on its shares of common stock.

For the years ended December 31, 2024 and 2023, the grant date fair value of all option grants was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions:

	Year Ended December 31,
	2024			2023
Expected term (in years)		6.46			7.49
Expected volatility		77.93	%		74.58	%
Risk-free rate		3.91	%		4.38	%
Dividend rate		0.00	%		0.00	%

Restricted Stock Units

Restricted stock units have been issued to certain board members. Activity in restricted stock units is summarized in the following table:

	Number of Units			Weighted-Average Grant Date Fair Value
Unvested at January 1, 2023		11,960		$	11.25
Granted		17,959		$	10.30
Vested		(17,944	)	$	10.93
Forfeited and expired		(9,710	)	$	10.30
Unvested at December 31, 2023		2,265		$	10.30
Vested		(2,265	)	$	10.30
Unvested at December 31, 2024		—		$	—

As of December 31, 2024, there was no unrecognized compensation expense related to restricted stock units.

Business and Geographical Reporting Segments

12 Months Ended

Dec. 31, 2024

Business and Geographical Reporting Segments [Abstract]

Business and Geographical Reporting Segments

14. Business and Geographical Reporting Segments

The Company has organized its business into two operating segments to better align its organization based upon the Company’s management structure, products and services offered, markets served and types of customers. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC and TheraClear procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense) is also not allocated to the operating segments.

The following tables present results of operations from the Company’s business segments for the periods indicated below (in thousands, except gross profit %):

Year Ended December 31, 2024	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	21,171		$	12,391		$	33,562
Cost of revenues		7,893			6,588			14,481
Gross profit		13,278			5,803			19,081
Gross profit %		62.7	%		46.8	%		56.9	%

Allocated expenses:
Engineering and product development		658			225			883
Selling and marketing		11,046			1,243			12,289
Impairment of goodwill		3,861			—			3,861
Unallocated expenses		—			—			11,303
Total allocated and unallocated expenses		15,565			1,468			28,336
(Loss) income from operations		(2,287	)		4,335			(9,255	)
Interest expense		—			—			(2,107	)
Interest income		—			—			242
Other income		—			—			864
(Loss) income before benefit from income taxes	$	(2,287	)	$	4,335		$	(10,256	)

Year Ended December 31, 2023	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	21,530		$	11,828		$	33,358
Cost of revenues		8,729			6,168			14,897
Gross profit		12,801			5,660			18,461
Gross profit %		59.5	%		47.9	%		55.3	%

Allocated expenses:
Engineering and product development		1,011			306			1,317
Selling and marketing		11,169			1,787			12,956
Impairment of goodwill		2,284			—			2,284
Unallocated expenses		—			—			10,508
Total allocated and unallocated expenses		14,464			2,093			27,065
(Loss) income from operations		(1,663	)		3,567			(8,604	)
Interest expense		—			—			(1,640	)
Interest income		—			—			231
Loss on debt extinguishment		—			—			(909	)
(Loss) income before benefit from income taxes	$	(1,663	)	$	3,567		$	(10,922	)

For the years ended December 31, 2024 and 2023, depreciation and amortization by reportable segment were as follows (in thousands):

	Year Ended December 31,
	2024		2023
Dermatology recurring procedures	$	4,471	$	4,793
Dermatology procedures equipment		485		746
Unallocated expenses		12		14
Total	$	4,968	$	5,553

The following tables present the Company’s revenue disaggregated by geographical region for the years ended December 31, 2024 and 2023 (in thousands). Domestic refers to revenue from customers based in the United States, and foreign revenue is derived from the Company’s distributors primarily in Asia.

Year Ended December 31, 2024	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	19,531	$	1,357	$	20,888
China		—		4,069		4,069
Other foreign		1,640		6,965		8,605
Total	$	21,171	$	12,391	$	33,562

Year Ended December 31, 2023	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	20,215	$	2,813	$	23,028
China		—		3,340		3,340
Other foreign		1,315		5,675		6,990
Total	$	21,530	$	11,828	$	33,358

As of December 31, 2024 and 2023, total assets by reportable segment were as follows (in thousands):

	December 31,
	2024		2023
Dermatology recurring procedures	$	21,750	$	28,137
Dermatology procedures equipment		5,081		5,507
Other unallocated assets		9,326		8,372
Total	$	36,157	$	42,016

Long-lived assets of $1.3 million and $0.8 million were located in international markets, primarily Korea and Japan, as of December 31, 2024 and 2023, respectively, with the remainder located in domestic markets.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

Basis of Presentation and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2024

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation:

Principles of Consolidation

The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). The accompanying consolidated financial statements include the accounts of the Company and Photomedex India Private Limited, its wholly-owned subsidiary in India. No operating activities have occurred within the Company’s subsidiary as of and during the years ended December 31, 2024 and 2023.

Reverse Stock Split

On October 26, 2023, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. On April 26, 2024, the Board of Directors approved the implementation of a reverse stock split at a ratio of one-for-ten shares, which became effective on June 6, 2024. The Company’s outstanding stock-based awards, including options, restricted stock units and warrants, were also adjusted to reflect the one-for-ten reverse stock split of the Company’s common stock. Outstanding stock-based award units were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity. No fractional shares were issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to a fractional share of common stock were instead entitled to receive a proportional cash payment. The reverse stock split did not change the par value or authorized number of shares of common stock. All share and per share amounts in these consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company’s significant estimates and judgments include revenue recognition with respect to deferred revenues and the contract term and valuation allowances of accounts receivable, inputs used when evaluating goodwill for impairment, inputs used in the valuation of contingent consideration, state sales and use tax accruals, the estimated useful lives of intangible assets, and the valuation allowance related to deferred tax assets. Actual results could differ from those estimates.

Concentrations of Credit Risk and Major Customers

The Company’s cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance coverage limit of $0.3 million per depositor, per FDIC-insured bank, per ownership category. Management has reviewed the financial statements of this institution and believes it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little credit risk to the Company.

Financial instruments that potentially subject the Company to concentrations of credit risk principally consist of cash equivalents and accounts receivable. The Company limits its credit risk associated with cash equivalents by placing investments in highly-rated money market funds. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary, but it does not require collateral to secure amounts owed by its customers.

The Company had one customer, an international distributor, from which it primarily earns dermatology procedures equipment revenues, that accounted for 10% or more of the Company’s revenues for each of the years ended December 31, 2024 and 2023. Revenues from this customer were $4.1 million and $3.3 million, or 12.1% and 10.0%, of total net revenues during the years ended December 31, 2024 and 2023, respectively. There were no accounts receivable associated with this customer as of December 31, 2024 and 2023. Accounts receivable associated with two other customers as of December 31, 2024 and one other customer as of December 31, 2023, each of which accounted for 10% or more of the Company’s net accounts receivable, was $2.2 million and $0.7 million, or 42.2% and 16.5%, of net accounts receivable as of December 31, 2024 and 2023, respectively.

Cash and Cash Equivalents

The Company considers all highly-liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2024 and 2023, cash equivalents consisted of credit card transactions with settlement terms of less than five days.

Restricted Cash

As discussed more fully in Note 10, the Company was required to post an appellate bond for $1.3 million in the form of cash collateral with respect to a sales tax determination by the State of New York Tax Appeals Tribunal (“Tribunal”). As the result of an adverse decision received by the Company in October 2024, the State of New York will execute on the appellate bond.

The cash collateral is recorded as restricted cash on the consolidated balance sheets as of December 31, 2024 and 2023. The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2024		2023
Cash and cash equivalents	$	7,261	$	6,784
Restricted cash		1,334		1,334
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	8,595	$	8,118

Accounts Receivable and Allowance for Credit Losses

Accounts receivable primarily relates to amounts due from customers, which are typically due within 30 to 90 days from invoice date. The Company provides credit to its customers in the normal course of business and maintains allowances for expected credit losses over the remaining contractual lives of its receivables, considering customer financial condition, historical loss experience with customers, current market economic conditions and forecasts of future economic conditions when appropriate. The Company does not require collateral or other security for accounts receivable. The Company also maintains allowances for estimated losses resulting from amounts deemed to be uncollectible from its customers. These allowances are for specific amounts on certain customer accounts based on facts and circumstances determined on a case-by-case basis. The Company writes off accounts receivable when they are considered uncollectible, and payments subsequently received on such receivables are credited to bad debt expense. The Company does not recognize interest accruing on accounts receivable past due.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined based on purchased cost for raw materials and all production cost related to the laser manufacturing process (labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods is classified as inventory. For the Company’s products, cost is determined on the first-in, first-out method. Work-in-process is immaterial, given the typically short manufacturing cycle and therefore, is disclosed in conjunction with raw materials.

The Company’s equipment for the treatment of skin disorders (e.g. the XTRAC) will either (i) be placed in a physician’s office and remain the property of the Company (at which date such equipment is transferred to property and equipment) or (ii) be sold to distributors or physicians directly. The cost to build a laser for sale is accumulated in inventory, and the cost to build a laser for placement is accumulated in property and equipment.

Reserves for slow-moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trends.

Property and Equipment, net

Property and equipment are recorded at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are capitalized. Upon retirement or disposition, the applicable property and equipment amounts are deducted from the accounts and any gain or loss is recorded in the consolidated statements of operations. Depreciation and amortization are recognized using the straight-line method based on the estimated useful lives of the related assets. The Company uses an estimated useful life of three years for computers, hardware and software, five years for machinery and equipment, seven years for furniture and fixtures, and the lesser of the useful life or lease term for leasehold improvements.

Intangible Assets

Intangible assets consist of core technology, product technology, customer relationships, trademarks and distribution rights. Intangible assets are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from three to 12 years.

Goodwill

Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized, but is subject to an annual impairment test. The Company has two reporting units and goodwill is allocated to the reporting units (see Note 14).

The Company performs its goodwill impairment test on an annual basis in the fourth quarter of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded for the amount by which the carrying amount of the reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. In conjunction with the annual budgeting process during the fourth quarter of 2023 and using data collected since the official launch of the TheraClear devices, the Company reduced its projected earnings from TheraClear devices. Similarly, in conjunction with the annual budgeting process during the fourth quarter of 2024, the Company reduced its overall projected earnings. As a result, the Company bypassed the qualitative assessments of goodwill impairment and performed quantitative assessments by comparing the fair value of each reporting unit with its carrying amount. The Company recorded impairment charges of $3.9 million and $2.3 million related to goodwill during the years ended December 31, 2024 and 2023, respectively, which was the amount of the excess of the carrying value of the dermatology recurring procedures reporting unit over its fair value. The impairments were primarily driven by a decline in projected cash flows, including revenues and profitability. The fair values of the reporting units were determined using both a market and income approach, with the market approach given a 25% weighting and the income approach given a 75% weighting. Significant assumptions used in the income approach include growth and discount rates, profit margins and the Company’s weighted average cost of capital. Historical performance and management estimates of future performance were used to determine profit margins and growth rates.

The impairment charges are included in impairment of goodwill within the consolidated statements of operations for the years ended December 31, 2024 and 2023. The dermatology procedures equipment reporting unit was not identified as having impairment for the years ended December 31, 2024 and 2023.

Impairment of Long-Lived Assets and Intangibles

The Company reviews its long-lived assets and intangible assets subject to amortization for impairment whenever events or changes in circumstances indicate the carrying amount of an asset group may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset group to future net cash flows expected to be generated by the asset group. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group, less costs to sell. The Company did not record any charges related to asset impairment during the years ended December 31, 2024 and 2023.

Fair Value Measurements

The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires the use of observable inputs and minimizes the use of unobservable inputs. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

•	Level 1 – quoted market prices in active markets for identical assets or liabilities.

•

Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•	Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

Accrued Warranty Costs

The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold.

The activity in the warranty accrual during the years ended December 31, 2024 and 2023 is summarized as follows (in thousands):

	December 31,
	2024			2023
Balance, beginning of year	$	303		$	207
Additions		156			237
Expirations and claims satisfied		(144	)		(141	)
Total		315			303
Less current portion within accrued expenses and other current liabilities		(213	)		(180	)
Balance within deferred revenues and other liabilities	$	102		$	123

Debt Issuance Costs

The Company capitalizes direct costs incurred to obtain debt financing and amortizes these costs to interest expense over the term of the debt using the effective interest method. These costs are recorded as a debt discount and are netted against the related debt on the Company’s consolidated balance sheets.

Contingent Consideration

In January 2022, the Company acquired certain assets related to the TheraClear devices from Theravant Corporation (“Theravant”). Theravant is eligible to receive future earnout payments upon the achievement of certain net revenue, gross profit and commercialization milestones (see Note 10). Due to uncertainties associated with the development of a new product line and the use of estimates and assumptions to determine the fair value of the contingent consideration, the amount ultimately paid in connection with the earnout may differ from the estimated fair value at the acquisition date. As the transaction was accounted for as an asset acquisition, a revaluation of the contingent consideration would only be required if there is a significant change to the underlying valuation assumptions. The contingent consideration will be adjusted when the contingency is resolved and the consideration is paid or becomes payable. Any difference between the cash payment and the amount accrued for contingent consideration will result in an adjustment to the technology intangible asset. Contingent consideration expected to be paid within the next year is classified as current on the consolidated balance sheet.

During 2023, the Company revised its projections of expected revenues and gross profits to be earned from TheraClear devices. The change in projections was considered significant enough to warrant a revaluation of the contingent consideration. To calculate the fair value of the earnout at December 31, 2023, using Monte Carlo simulations, Company projections were utilized to develop expected revenues and gross profits based on the risk inherent in the projections using the Geometric-Brownian motion for the earnout periods and related earnout payments. Significant assumptions used in the Geometric-Brownian motion analysis include projected revenues, projected gross profit, risk free rate of return of 3.8%, revenue volatility of 15.0%, and a cost of equity of 10.0%. The fair value of the contingent consideration as of December 31, 2023 was estimated to be $1.2 million, which resulted in a reduction in contingent consideration of $7.4 million with a corresponding adjustment to the carrying value of the product technology intangible asset. During 2024, there were no further significant changes to the Company’s projections of expected revenues and gross profits to be earned from TheraClear devices and, as such, the Company did not revalue the contingent consideration.

Revenue Recognition

Revenues from the Company’s dermatology recurring procedures customers are earned by providing physicians with its laser products and charging the physicians a fee for a fixed number of treatment sessions or a fixed fee for a specified period of time not to exceed an agreed upon number of treatments; if that number is exceeded additional fees will have to be paid. The placement of the laser products at physician locations represents embedded leases which are accounted for as operating leases. For the lasers placed-in service under these arrangements, the terms of the domestic arrangements are generally 36 months with automatic one-year renewals and include a termination clause that can be effected at any time by either party with 30 to 60 day notice. Amounts paid are generally non-refundable. Sales of access codes for a fixed number of treatment sessions are considered variable treatment code payments and are recognized as revenue over the estimated usage period of the agreed upon number of treatments. Sales of access codes for a specified period of time are recognized as revenue on a straight-line basis as the lasers are being used over the term specified in the agreement. Variable treatment code payments that will be paid only if the customer exceeds the agreed upon number of treatments are recognized only when such treatments are being exceeded and used. Internationally, the Company generally sells access codes for a fixed amount on a monthly basis to its distributors and the terms are generally 48 months, with termination in the event of the customers’ failure to remit payments timely, and include a potential buy-out at the end of the term of the contract. Currently, this is the only foreign recurring revenue. Prepaid amounts recorded in deferred revenue and customer deposits recorded in accounts payable are recognized as revenue over the lease term in the patterns described above. Pricing is fixed with the customer. With respect to lease and non-lease components, the Company adopted the practical expedient to account for the arrangement as a single lease component.

Revenues from the Company’s dermatology procedures equipment are recognized when control of the promised goods or services is transferred to its customers or distributors, in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. Accordingly, the Company determines revenue recognition through the following steps:

•

identification of the contract, or contracts, with a customer;

•

identification of the performance obligations in the contract;

•

determination of the transaction price;

•

allocation of the transaction price to the performance obligations in the contract; and

•

recognition of revenue when, or as, performance obligations are satisfied.

Accounting for the Company’s contracts involves the use of significant judgments and estimates including determining the separate performance obligations, allocating the transaction price to the different performance obligations and determining the method to measure the entity’s performance toward satisfaction of performance obligations that most faithfully depicts when control is transferred to the customer. The Company allocates the contract’s transaction price to each performance obligation using the Company’s best estimate of the standalone selling price for each distinct good or service in the contract. The Company maximizes the use of observable inputs by beginning with average historical contractual selling prices and adjusting as necessary and on a consistent and rational basis for other inputs such as pricing trends, customer types, volumes and changing cost and margins.

Revenues from dermatology procedures equipment are recognized when control of the promised products is transferred to either the Company’s distributors or end-user customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products (the transaction price). Control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment and legal title must have passed to the customer. The Company ships most of its products FOB shipping point, and as such, the Company primarily transfers control and records revenue upon shipment. From time to time the Company will grant certain customers, for example governmental customers, FOB destination terms, and the transfer of control for revenue recognition occurs upon receipt. The Company has elected to recognize the cost of freight and shipping activities as fulfillment costs. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenues.

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2024		2023
Dermatology recurring procedures	$	21,171	$	21,530
Dermatology procedures equipment		12,391		11,828
Total net revenues	$	33,562	$	33,358

Years ending December 31:
2025	$	1,775
2026		1,586
2027		1,323
2028		790
	$	5,474

Remaining performance obligations related to ASC 606 represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year, which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include the potential obligation to perform under extended warranties and service contracts but exclude any dermatology procedures equipment accounted for as leases. As of December 31, 2024 and 2023, the aggregate amount of the transaction price allocated to remaining performance obligations was $0.5 million and $0.7 million, respectively, and the Company expects to recognize $0.2 million and $0.3 million, respectively, of the remaining performance obligations within one year and the remainder over one to three years. Contract assets primarily relate to the Company’s rights to consideration for work completed in relation to its services performed but not billed at the reporting date. The contract assets are transferred to receivables when the rights become unconditional. Currently, the Company does not have any contract assets which have not transferred to a receivable.

Contract liabilities primarily relate to extended warranties and service contracts where the Company has received payments but has not yet satisfied the related performance obligations. The allocations of the transaction price are based on the price of standalone warranty contracts sold in the ordinary course of business. The advance consideration received from customers for the warranty services is a contract liability that is recognized ratably over the warranty period. As of December 31, 2024 and 2023, the $0.2 million and $0.3 million of short-term contract liabilities, respectively, is presented as deferred revenues and the $0.3 million and $0.4 million of long-term contract liabilities, respectively, is presented within deferred revenues and other liabilities on the consolidated balance sheets. For the years ended December 31, 2024 and 2023, the Company recognized $0.3 million and $0.4 million, respectively, as revenue from amounts classified as contract liabilities (i.e. deferred revenues) as of December 31, 2023 and 2022.

With respect to contract acquisition costs, the Company applies the practical expedient and expenses these costs immediately.

Engineering and Product Development

Engineering and product development costs associated with research, new product development and product redesign are expensed as incurred.

Advertising Costs

Advertising costs are expensed as incurred and included in selling and marketing expenses within the Company’s consolidated statements of operations. The Company recognized advertising costs of $1.0 million and $0.5 million during the years ended December 31, 2024 and 2023, respectively.

Stock-Based Compensation

The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the requisite service period of the awards.

Estimating the fair value of share-based awards requires the input of subjective assumptions, including the expected life of the options and stock price volatility. The Company accounts for forfeitures of stock option awards as they occur. The estimated fair value of restricted stock awards is equal to the Company’s common stock price at the grant date. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in estimating the fair value of stock-option awards represent management’s estimate and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

Income Taxes

The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities, as well as on net operating loss carryforwards, and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is not more likely than not that all or some portion of the deferred tax asset will be realized.

The Company recognizes the tax effects of uncertain tax positions only if the position is “more-likely-than-not” to be sustained were it to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the “more-likely-than-not” threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded. The Company has no uncertain tax positions as of December 31, 2024. The Company includes interest and penalties related to income tax obligations within income tax expense. The Company’s tax years are still under open status from 2021 to present.

Employee Retention Credit

The Employee Retention Credit (“ERC”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) is a refundable tax credit which encouraged businesses to keep employees on the payroll during the COVID-19 pandemic. Eligible employers could qualify for up to $7.0 thousand of credit for each employee based on qualified wages paid after December 31, 2020 and before January 1, 2022. Qualified wages are any wages paid to an employee (for employers that averaged fewer than 100 full-time employees in 2019) or the wages paid to an employee for the time that the employee is providing and not providing services (for employers that averaged more than 500 full-time employees in 2019) due to an economic hardship, specifically, either (1) a full or partial suspension of operations by order of a governmental authority due to COVID-19, or (2) a significant decline in gross receipts. The Company recognized $0.9 million of ERC as other income in the consolidated statement of operations for the year ended December 31, 2024. There was no such activity for the year ended December 31, 2023.

Net Loss Per Share

Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities such as unvested restricted stock awards, stock options and warrants for common stock which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same as for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2024		2023
Stock options		521,726		772,864
Common stock warrants		80,000		80,000
Restricted stock units		2,265		2,265
		603,991		855,129

Accounting Pronouncements Recently Adopted

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s own Equity. The pronouncement simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, the ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for it and simplifies the diluted earnings per share (EPS) calculations in certain areas. The guidance is effective for annual periods, including interim periods, beginning after December 15, 2023 with early adoption permitted. The adoption of this guidance on January 1, 2024 did not have an impact on the consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which primarily requires enhanced disclosures about significant segment expenses and information used to assess segment performance and enhanced disclosures in interim periods. The guidance in this ASU was effective for fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 15, 2024. The Company adopted the guidance in ASU 2023-07 for the year ended December 31, 2024, and it is being applied retrospectively to its consolidated financial statement disclosures.

Recent Accounting Pronouncements Not Yet Adopted

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in this ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements and footnote disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as subsequently amended by ASU 2025-01 to clarify the effective date, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements and footnote disclosures.

Long-term Debt, Future Minimum Principal Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Future Payments for Long-Term Debt [Abstract]
2026	$ 3,750
2027	7,500
2028	3,750
Total	15,000
Exit fee	600
Long term debt after exit fee	15,600
Less: unamortized debt discount	(408)
Long-term debt, net	$ 15,192	$ 15,044

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Organization and Nature of Business	12 Months Ended
Organization and Nature of Business	Dec. 31, 2024
The Company [Abstract]
Organization and Nature of Business	1. Organization and Nature of Business Background STRATA Skin Sciences, Inc. (the “Company”) is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. In January 2022, the Company acquired the TheraClear Acne Therapy System, or TheraClear device, to broaden its opportunities with expansion potential in the acne care market. The Company markets the device under the brand name TheraClear® X. Post-COVID-19 Pandemic Since March 2020, the global pandemic related to a new strain of coronavirus (“COVID-19”) has negatively impacted business conditions in the industry in which the Company operates, disrupted global supply chains, constrained workforce participation and created significant volatility and disruption of financial markets. The pandemic led to the suspension of elective procedures in the U.S. and to the temporary closure of many physician practices, which are the Company’s primary customers. While most physician offices have reopened, some of the Company’s partner physician practices closed permanently. Accordingly, the COVID-19 pandemic and its variants have negatively impacted the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frames and those of its primary customers. It has also negatively impacted the Company’s supply chains and transport, customer behavior and staffing. Impact of Russia-Ukraine War Prior to the outbreak of the Russia-Ukraine War, Ukraine was the largest exporter of noble gases including neon, krypton, and xenon and has historically been the source of a significant amount of gas supplied to the Company by its contract suppliers. Neon gas is essential to the proper functioning of the Company’s lasers. The Company’s suppliers have been resourceful in continuing to supply gases to the Company but cannot assure the Company that the supply will remain uninterrupted. The reduced supply and ongoing conflict have also impacted the price of gas worldwide. Additionally, the Creating Helpful Incentives to Produce Semiconductors and Science Act of 2022 has led to a further tightening of rare gas supplies as semiconductor chip manufacturers reconfigure their supply chains to address the need to secure their own supplies of rare gases for use in the manufacture of computer chips. Impact of Middle East Conflict The Company has not seen an impact on its distributors’ businesses in the Middle East due to the Middle East conflict, but cannot predict the impact should the conflict continue or develop into a larger war. Liquidity and Going Concern The Company has been negatively impacted by the COVID-19 pandemic, has historically experienced recurring losses, has been dependent on raising capital from the sale of securities in order to continue to operate and has been required to restrict cash for sales tax liabilities (see Note 10). In October 2021, the Company entered into an equity distribution agreement with an investment bank under which the Company may sell up to an additional $8.9 million of its common stock in registered “at-the-market” offerings. Management believes that the Company’s cash and cash equivalents, combined with the anticipated revenues from the sale or use of its products and operating expense management, will be sufficient to satisfy the Company’s working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with its existing operations for at least the next 12 months following the date of the issuance of these consolidated financial statements. However, market conditions, including the negative impact of the COVID-19 pandemic, the Russia-Ukraine War, and the Middle East conflict on the financial markets, supply chain disruptions, customer behavior, and rising interest rates, could interfere with the Company’s ability to access financing and on favorable terms.

Stock-Based Compensation, Stock Options (Details) - Stock Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Number of Shares under Option Plan [Abstract]
Outstanding at beginning of period (in shares)	772,864	447,462
Granted (in shares)	70,000	454,504
Forfeited and expired (in shares)	(321,138)	(129,102)
Outstanding at end of period (in shares)	521,726	772,864
Exercisable at end of period (in shares)	208,671
Vested and expected to vest (in shares)	521,726
Weighted Average Exercise Price per Option [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 11.07	$ 17.2
Granted (in dollars per share)	3.22	6.31
Forfeited and expired (in dollars per share)	14.07	15.59
Outstanding at end of period (in dollars per share)	8.16	$ 11.07
Exercisable at end of period (in dollars per share)	12.21
Vested and expected to vest (in dollars per share)	$ 8.16
Weighted Average Remaining Contractual Term [Abstract]
Outstanding	7 years 10 months 17 days	6 years 8 months 12 days
Exercisable	6 years 3 months 25 days
Vested and expected to vest	7 years 10 months 17 days
Weighted-average grant date fair value (in dollars per share)	$ 2.27	$ 4.43
Unrecognized compensation expense	$ 1,000,000
Unrecognized compensation expense, weighted average period	2 years 4 months 9 days
Aggregate intrinsic value of options outstanding	$ 8,000	$ 100,000
Aggregate intrinsic value of options exercisable	0	0
Aggregate intrinsic value of options exercised	$ 0	$ 0
Expiration period	10 years

Business and Geographical Reporting Segments (Tables)

12 Months Ended

Dec. 31, 2024

Business and Geographical Reporting Segments [Abstract]

Segment Reporting Information by Segment

The following tables present results of operations from the Company’s business segments for the periods indicated below (in thousands, except gross profit %):

Year Ended December 31, 2024	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	21,171		$	12,391		$	33,562
Cost of revenues		7,893			6,588			14,481
Gross profit		13,278			5,803			19,081
Gross profit %		62.7	%		46.8	%		56.9	%

Allocated expenses:
Engineering and product development		658			225			883
Selling and marketing		11,046			1,243			12,289
Impairment of goodwill		3,861			—			3,861
Unallocated expenses		—			—			11,303
Total allocated and unallocated expenses		15,565			1,468			28,336
(Loss) income from operations		(2,287	)		4,335			(9,255	)
Interest expense		—			—			(2,107	)
Interest income		—			—			242
Other income		—			—			864
(Loss) income before benefit from income taxes	$	(2,287	)	$	4,335		$	(10,256	)

Year Ended December 31, 2023	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	21,530		$	11,828		$	33,358
Cost of revenues		8,729			6,168			14,897
Gross profit		12,801			5,660			18,461
Gross profit %		59.5	%		47.9	%		55.3	%

Allocated expenses:
Engineering and product development		1,011			306			1,317
Selling and marketing		11,169			1,787			12,956
Impairment of goodwill		2,284			—			2,284
Unallocated expenses		—			—			10,508
Total allocated and unallocated expenses		14,464			2,093			27,065
(Loss) income from operations		(1,663	)		3,567			(8,604	)
Interest expense		—			—			(1,640	)
Interest income		—			—			231
Loss on debt extinguishment		—			—			(909	)
(Loss) income before benefit from income taxes	$	(1,663	)	$	3,567		$	(10,922	)

Disaggregation of Revenue by Geographical Region

Year Ended December 31, 2024	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	19,531	$	1,357	$	20,888
China		—		4,069		4,069
Other foreign		1,640		6,965		8,605
Total	$	21,171	$	12,391	$	33,562

Year Ended December 31, 2023	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	20,215	$	2,813	$	23,028
China		—		3,340		3,340
Other foreign		1,315		5,675		6,990
Total	$	21,530	$	11,828	$	33,358

Depreciation and Amortization by Reportable Segment

For the years ended December 31, 2024 and 2023, depreciation and amortization by reportable segment were as follows (in thousands):

	Year Ended December 31,
	2024		2023
Dermatology recurring procedures	$	4,471	$	4,793
Dermatology procedures equipment		485		746
Unallocated expenses		12		14
Total	$	4,968	$	5,553

Total Assets by Reportable Segment

As of December 31, 2024 and 2023, total assets by reportable segment were as follows (in thousands):

	December 31,
	2024		2023
Dermatology recurring procedures	$	21,750	$	28,137
Dermatology procedures equipment		5,081		5,507
Other unallocated assets		9,326		8,372
Total	$	36,157	$	42,016

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2024

Income Taxes [Abstract]

Components of Income Tax Expense

Income tax expense consists of the following (in thousands):

	Year Ended December 31,
	2024			2023
Current:
Federal	$	—		$	—
State		16			28
		16			28
Deferred:
Federal		(107	)		(68	)
State		(79	)		(52	)
		(186	)		(120	)
Benefit from income taxes	$	(170	)	$	(92	)

Components of Deferred Tax Liability for Federal Income Taxes

Significant components of the Company’s deferred tax liability for federal income taxes consisted of the following (in thousands):

	December 31,
	2024			2023
Deferred tax assets:
Net operating loss carryforwards	$	46,295		$	46,718
Intangible assets		2,308			2,138
Inventories		57			71
Reserves and accrued expenses		2,068			1,381
Stock-based compensation		162			180
Operating lease liabilities		305			145
Interest expense limitation carryover		1,024			552
Goodwill		239			—
Gross deferred tax assets		52,458			51,185
Less: valuation allowance		(51,671	)		(50,139	)
		787			1,046
Deferred tax liabilities:
Property and equipment		(478	)		(412	)
Operating lease right-of-use assets		(309	)		(154	)
Goodwill		—			(666	)
		(787	)		(1,232	)
Net deferred tax liability	$	—		$	(186	)

Net Operating Loss Carryforwards

The Company had net operating loss (“NOL”) carryforwards for federal and state income tax purposes as follows (in thousands):

	December 31,
	2024		2023
Federal	$	203,490	$	205,212
State	$	62,819	$	63,566

Reconciliation of Income Tax Expense

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:

	Year Ended December 31,
	2024			2023
Federal tax expense at statutory rate		21.00	%		21.00	%
State tax, net of federal benefit		(0.12	)%		0.18	%
Permanent differences		(1.15	)%		(1.89	)%
Other difference and true ups		(3.13	)%		(8.07	)%
Change in valuation allowance		(14.94	)%		(10.38	)%
Effective income tax rate		1.66	%		0.84	%

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2024
Stockholders' Equity [Abstract]
Stockholders' Equity	11. Stockholders’ Equity Preferred Stock The Company is authorized to issue preferred stock with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors. Other than the limitations on conversions to keep each such holder’s beneficial ownership below 9.99%, the terms of the Series C convertible preferred stock generally bestow the same rights to each holder as such holder would receive if they were common stock shareholders and are not redeemable by the holders, except that the Series C convertible preferred stock shares do not have voting rights. Each share of Series C convertible preferred stock has a stated value of $1.0 thousand and is convertible into shares of common stock at a conversion price equal to $26.90. No preferred shares were outstanding as of December 31, 2024 and 2023. Common Stock The Company issued 33,779 shares upon the vesting of restricted stock during the year ended December 31, 2023. No shares were issued upon the vesting of restricted stock during the year ended December 31, 2024. In October 2021, the Company entered into an equity distribution agreement under which the Company may sell up to $11.0 million of its shares of common stock in registered “at-the-market” offerings. The shares will be offered at prevailing market prices, and the Company will pay commissions of up to 3.0% of the gross proceeds from the sale of shares sold through the Company’s agent, which may act as an agent and/or principal. The Company has no obligation to sell any shares under this agreement and may, at any time, suspend solicitations under this agreement. In July 2024, the Company sold 665,136 shares of its common stock under the equity distribution agreement at an average purchase price of $3.16 per share for total gross and net proceeds of $2.1 million and $1.9 million, respectively. No shares of the Company’s common stock were sold under this distribution agreement during the year ended December 31, 2023. As of December 31, 2024, the Company may sell up to an additional $8.9 million of its shares of common stock under the equity distribution agreement. Common Stock Warrants In September 2021 and in connection with entering into the Company’s Senior Term Facility (Note 9), the Company issued a warrant to purchase 37,362 shares of the Company’s common stock at an initial exercise price of $18.20 per share. The warrant was amended in June 2023 in connection with the execution of the Third Amendment to the Senior Term Facility. The amended warrant is to purchase 80,000 shares of the Company’s common stock at an exercise price equal to $8.80 per share. The warrant is equity classified and is exercisable at any time on or prior to the tenth anniversary of its amendment date. As of December 31, 2024, the warrant remains outstanding in its entirety.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Accrued Expenses and Other Current Liabilities [Abstract]
Warranty obligations	$ 213	$ 180
Compensation and related benefits	1,781	1,679
State sales, use and other taxes	6,371	4,316
Professional fees and other	228	131
Accrued expenses and other current liabilities	$ 8,593	$ 6,306

Intangible Assets and Goodwill, Estimated Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Estimated amortization expense [Abstract]
2025	$ 1,266
2026	561
2027	561
2028	561
2029	$ 561

Basis of Presentation and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2024

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Principles of Consolidation

Basis of Presentation:

Principles of Consolidation

Reverse Stock Split

Use of Estimates

Concentrations of Credit Risk and Major Customers

Cash and Cash Equivalents

Restricted Cash

	December 31,
	2024		2023
Cash and cash equivalents	$	7,261	$	6,784
Restricted cash		1,334		1,334
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	8,595	$	8,118

Accounts Receivable and Allowance for Credit Losses

Inventories

Property and Equipment, net

Intangible Assets

Goodwill

Impairment of Long-Lived Assets and Intangibles

Fair Value Measurements

•	Level 1 – quoted market prices in active markets for identical assets or liabilities.

•

•	Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

Accrued Warranty Costs

The activity in the warranty accrual during the years ended December 31, 2024 and 2023 is summarized as follows (in thousands):

	December 31,
	2024			2023
Balance, beginning of year	$	303		$	207
Additions		156			237
Expirations and claims satisfied		(144	)		(141	)
Total		315			303
Less current portion within accrued expenses and other current liabilities		(213	)		(180	)
Balance within deferred revenues and other liabilities	$	102		$	123

Debt Issuance Costs

Contingent Consideration

Revenue Recognition

•

identification of the contract, or contracts, with a customer;

•

identification of the performance obligations in the contract;

•

determination of the transaction price;

•

allocation of the transaction price to the performance obligations in the contract; and

•

recognition of revenue when, or as, performance obligations are satisfied.

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2024		2023
Dermatology recurring procedures	$	21,171	$	21,530
Dermatology procedures equipment		12,391		11,828
Total net revenues	$	33,562	$	33,358

Years ending December 31:
2025	$	1,775
2026		1,586
2027		1,323
2028		790
	$	5,474

With respect to contract acquisition costs, the Company applies the practical expedient and expenses these costs immediately.

Engineering and Product Development

Engineering and product development costs associated with research, new product development and product redesign are expensed as incurred.

Advertising Costs

Stock-Based Compensation

The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the requisite service period of the awards.

Income Taxes

Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2024		2023
Stock options		521,726		772,864
Common stock warrants		80,000		80,000
Restricted stock units		2,265		2,265
		603,991		855,129

Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted

Accounting Pronouncements Recently Adopted

Recent Accounting Pronouncements Not Yet Adopted

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Remaining Performance Obligation (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Remaining Performance Obligation [Abstract]
Remaining performance obligations	$ 0.5	$ 0.7
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Remaining Performance Obligation [Abstract]
Remaining performance obligations		$ 0.3
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| Minimum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| Maximum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period		3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Remaining Performance Obligation [Abstract]
Remaining performance obligations	$ 0.2
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| Minimum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| Maximum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	3 years

Business and Geographical Reporting Segments, Total Assets by Reportable Segment (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Total Assets by Reportable Segment [Abstract]
Assets	$ 36,157	$ 42,016
International [Member]
Long-lived Assets [Abstract]
Long-lived assets	1,300	800
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Total Assets by Reportable Segment [Abstract]
Assets	21,750	28,137
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Total Assets by Reportable Segment [Abstract]
Assets	5,081	5,507
Other Unallocated Assets [Member]
Total Assets by Reportable Segment [Abstract]
Assets	$ 9,326	$ 8,372

- Definition

Amount of asset recognized for present right to economic benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2024
Fair Value Measurements [Abstract]
Fair Value Measurements	3. Fair Value Measurements The carrying values of cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, and accounts payable on the Company’s consolidated balance sheets approximated their fair values as of December 31, 2024 and 2023 due to their short-term nature. The carrying value of the Company’s Senior Term Facility (see Note 9) approximated its fair value as of December 31, 2024 and 2023 due to its variable interest rate.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Legal Matters In the ordinary course of business, the Company is routinely a defendant in or party to pending and threatened legal actions and proceedings, including actions brought on behalf of various classes of claimants. These actions and proceedings are generally based on alleged violations of employment, contract, and other laws. In some of these actions and proceedings, claims for substantial monetary damages are asserted against the Company. In the ordinary course of business, the Company is also subject to regulatory and governmental examinations, information gathering requests, inquiries, investigations, and threatened legal actions and proceedings. In connection with formal and informal inquiries by federal, state, local and foreign agencies, the Company receives numerous requests, subpoenas and orders for documents, testimony, and information in connection with various aspects of its activities. Accrued State Sales and Use Tax Matters The Company records state sales tax collected and remitted for its customers on dermatology procedures equipment sales on a net basis, excluded from revenue. The Company’s sales tax expense that is not presently being collected and remitted for the recurring revenue business is recorded in general and administrative expenses within the consolidated statements of operations. The Company believes its state sales and use tax accruals have been properly recognized such that, if the Company’s arrangements with customers are deemed more likely than not that the Company would not be exempt from sales tax in a particular state, the basis for measurement of the state sales and use tax is calculated in accordance with ASC 405, Liabilities, as a transaction tax. If and when the Company is successful in defending itself or in settling the sales tax obligation for a lesser amount, the reversal of this liability is to be recorded in the period the settlement is reached. However, the precise scope, timing, and time period at issue, as well as the final outcome of any audit and actual settlement, remains uncertain. In the ordinary course of business, the Company is, from time to time, subject to audits performed by state taxing authorities. These actions and proceedings are generally based on the position that the arrangements entered into by the Company are subject to sales and use tax rather than exempt from tax under applicable law. The states of New York and California have assessed the Company an aggregate of $5.2 million including penalties and interest. The audits cover the period from March 2014 through November 2022. The Company received notification that an administrative state judge in New York issued an opinion finding in favor of the Company that the sale of XTRAC treatment codes was not taxable as sales tax with respect to that state’s first assessment. This ruling covers $1.8 million of the total $5.2 million of assessments. The relevant taxing authority filed an appeal of the administrative law judge’s finding and, following the submission of legal briefs by both sides and oral argument held in January 2022, on May 6, 2022, the Company received a written decision from the Tribunal overturning the favorable sales tax determination of the administrative law judge. The Company appealed the Tribunal’s decision to the New York State Appellate Division (“Appellate Division”), and posted the required appellate bond in the form of cash collateral. Oral argument was held by the Appellate Division on January 18, 2024. On March 8, 2024, the Company received a decision from the Appellate Division ruling against it in the matter of its sales tax appeal, affirming the Tribunal’s ruling that the Company’s sale of XTRAC treatment codes is subject to sales tax. The Appellate Division concluded that, through the usage arrangements, the Company’s customers had possession of the laser devices and had a license and ability to use the laser devices. The Appellate Division also agreed with the Tribunal that the primary function analysis was not applicable in this matter. On April 11, 2024, the Company filed a motion for leave to appeal the Appellate Division’s decision to the New York State Court of Appeals (“Court of Appeals”). On October 22, 2024, in an unsigned one-line decision, the Court of Appeals denied the Company’s motion to appeal the Appellate Division ruling. Therefore, the adverse decision stands and New York will execute on the appellate bond the Company posted for $1.3 million. As of September 30, 2024, the Company has accrued $1.8 million including penalties and interest as a result of the Appellate Division ruling. The Company is in the administrative process of appeal with respect to the remaining $1.3 million of assessments in the State of New York. The Company believes that the Appellate Division ruling provides an avenue for challenging the pending audit periods and subsequent periods, provided the Company can show that the value of the equipment provided to customers is either incidental to the overall value of the non-taxable services that are provided or should be treated similarly to pharmaceutical treatments, which are generally exempt from sales tax. The State of California has made aggregate assessments of $2.1 million including penalties and interest. The audits cover the period from June 2018 through June 2022. The Company is in the administrative process of appeal in this jurisdiction as well. In those states where we did not or may not prevail in the future with the defenses we have proposed and in the event there is a determination that the true object of the Company’s recurring revenue model is not exempt from sales taxes and is not a prescription medicine, or the Company does not have other defenses where the Company prevails, the Company may be subject to sales taxes in those particular states for previous years and in the future, plus potential interest and penalties. The precise scope, timing and time periods at issue, as well as the final outcomes of the investigations and judicial proceedings, remain uncertain. Accordingly, the Company’s estimate may change from time to time, and actual losses could vary. Employee 401(k) Savings Plan The Company sponsors a 401(k) defined contribution retirement savings plan that covers all eligible employees who have met the minimum age and service requirements. Under the plan, eligible employees may contribute a portion of their annual compensation into the plan up to IRS annual limits. The Company has elected to make matching contributions to the plan based on a percentage of the employee’s contribution. For the years ended December 31, 2024 and 2023, the Company’s contributions to the plan were $0.3 million and $0.4 million, respectively. Contingent Consideration In connection with the Company’s acquisition of certain assets related to the TheraClear devices, Theravant is eligible to receive up to $3.0 million in future earnout payments upon the achievement of certain annual net revenue milestones ($1.0 million of which is due upon the earlier of achieving a revenue target or July 2025), up to $20.0 million in future royalty payments based upon a percentage of gross profit from future domestic sales ranging from 10-20%, 25% of gross profit from international sales over the subsequent four-year period, and up to $0.5 million in future milestone payments upon the achievement of certain commercialization related targets. The Company has notified Theravant that it believes the earnout payments are not due and will not be due in the future. Theravant has disputed the Company’s contention and the matter is under discussion among the signatories to the purchase agreement. Through December 31, 2024, the Company has incurred an aggregate of $0.1 million of royalty and gross profit payments based on gross profit from domestic and international sales. Milestone Payments In January 2022, the Company entered into a Development Agreement (the “Development Agreement”) with Theravant. Under the Development Agreement, the Company will reimburse Theravant for costs incurred in further developing certain TheraClear technology and other healthcare products and methods for the medical aesthetic marketplace. In connection with the development of three devices, Theravant is eligible to receive $0.5 million upon FDA clearance for each device and $0.5 million upon achievement of certain net revenue targets for each device, aggregating to $3.0 million of potential future milestone payments under the Development Agreement. The Development Agreement had a three-year term, unless terminated sooner by either party, and expired in January 2025. The Development Agreement was being accounted for separately from the TheraClear asset acquisition. No milestone payments were incurred under the Development Agreement, nor does the Company anticipate that any such payments may be due in the future.

Stockholders' Equity, Preferred Stock and Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Jul. 31, 2024	Oct. 31, 2021	Dec. 31, 2024	Dec. 31, 2023
Class of Stock Disclosures [Abstract]
Preferred stock, stated value (in dollars per share)			$ 0.1	$ 0.1
Preferred shares outstanding (in shares)			0	0
Issuance of restricted stock (in shares)			0	33,779
Net proceeds from sale of common stock			$ 1,943	$ 0
At-the-Market Equity Offering [Member]
Class of Stock Disclosures [Abstract]
Amount of common stock the Company may sell under equity distribution agreement		$ 11,000
Issuance of common stock (in shares)	665,136			0
Common stock purchase price (in dollars per share)	$ 3.16
Gross proceeds from sale of common stock	$ 2,100
Net proceeds from sale of common stock	$ 1,900
At-the-Market Equity Offering [Member] \| Maximum [Member]
Class of Stock Disclosures [Abstract]
Commission as percentage of gross proceeds from sale of shares sold		3.00%
Amount of additional common stock Company may sell under equity distribution agreement		$ 8,900	$ 8,900
Series C Convertible Preferred Stock [Member]
Class of Stock Disclosures [Abstract]
Beneficial ownership percentage			9.99%
Preferred stock, stated value (in dollars per share)			$ 1,000
Preferred stock conversion price (in dollars per share)			$ 26.9

Stock-Based Compensation, Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Stock-Based Compensation Expense [Abstract]
Stock-based compensation expense	$ 427	$ 1,303
Selling and Marketing [Member]
Stock-Based Compensation Expense [Abstract]
Stock-based compensation expense	7	79
General and Administrative [Member]
Stock-Based Compensation Expense [Abstract]
Stock-based compensation expense	$ 420	$ 1,224

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2024

Stock-Based Compensation [Abstract]

Share-based Compensation Expense

The Company recorded share‑based compensation expense (for all awards and modifications, if any) in the accompanying consolidated statements of operations as follows (in thousands):

	Year Ended December 31,
	2024		2023
Selling and marketing	$	7	$	79
General and administrative		420		1,224
	$	427	$	1,303

Stock Option Activity

The following table summarizes stock option activity for the years ended December 31, 2024 and 2023:

	Number of Shares Under Option Plan			Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Term (in years)
Outstanding at January 1, 2023		447,462		$	17.20
Granted		454,504		$	6.31
Forfeited and expired		(129,102	)	$	15.59
Outstanding at December 31, 2023		772,864		$	11.07		6.70
Granted		70,000		$	3.22
Forfeited and expired		(321,138	)	$	14.07
Outstanding at December 31, 2024		521,726		$	8.16		7.88
Exercisable at December 31, 2024		208,671		$	12.21		6.32
Vested and expected to vest at December 31, 2024		521,726		$	8.16		7.88

Weighted Average Assumption Used for Grant Date Fair Value of Option Grants

	Year Ended December 31,
	2024			2023
Expected term (in years)		6.46			7.49
Expected volatility		77.93	%		74.58	%
Risk-free rate		3.91	%		4.38	%
Dividend rate		0.00	%		0.00	%

Summary of Activity in Restricted Stock Units

Restricted stock units have been issued to certain board members. Activity in restricted stock units is summarized in the following table:

	Number of Units			Weighted-Average Grant Date Fair Value
Unvested at January 1, 2023		11,960		$	11.25
Granted		17,959		$	10.30
Vested		(17,944	)	$	10.93
Forfeited and expired		(9,710	)	$	10.30
Unvested at December 31, 2023		2,265		$	10.30
Vested		(2,265	)	$	10.30
Unvested at December 31, 2024		—		$	—